

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 November 2003 (13.11.2003)

PCT

(10) International Publication Number
WO 03/093289 A1

(51) International Patent Classification⁷: **C07H 17/08**,
A61K 31/7048, A61P 31/04

TX 75225-4627 (US). **YONG, Hong**; 312 Cambridge Dr,
Grayslake, IL 60030 (US).

(21) International Application Number: PCT/US03/12971

(74) Agents: **DONNER, B., Gregory** et al.; D-377 AP6A-1,
100 Abbott Park Road, Abbott Park, IL 60064-6008 (US).

(22) International Filing Date: 25 April 2003 (25.04.2003)

(25) Filing Language: English

(81) Designated States (*national*): CA, JP, MX.

(26) Publication Language: English

(84) Designated States (*regional*): European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(30) Priority Data:

10/136,796	30 April 2002 (30.04.2002)	US
10/205,708	26 July 2002 (26.07.2002)	US
10/422,309	24 April 2003 (24.04.2003)	US

Published:


- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(71) Applicant: **ABBOTT LABORATORIES** [US/US];
D-377 AP6A-1, 100 Abbott Park Road, Abbott Park, IL
60064-6008 (US).


(72) Inventors: **GU, Yugui**; 1221 Virginia Ave, Libertyville,
IL 60048 (US). **MA, Zhenkun**; 7215 Marquette St, Dallas,

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS



(57) Abstract: Antibacterial compounds having for-
mula (I) and formula (II), and salts, prodrugs, and
salts of prodrugs thereof, processes for making the
compounds and intermediates used in the processes,
compositions containing the compounds, and meth-
ods for prophylaxis or treatment of bacterial infec-
tions using the compounds are disclosed.



TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS

FIELD OF THE INVENTION


This invention is directed to compounds which are useful as antibacterials, processes for making the compounds and intermediates used in the processes, compositions
5 containing the compounds, and methods for prophylaxis or treatment of bacterial infections using the compounds.

BACKGROUND OF THE INVENTION

Because the effectiveness of many drugs currently
10 available public use for prophylaxis or treatment of bacterial infections is compromised by the emergence of drug-resistant bacteria, novel antibacterial compounds would be beneficial for their therapeutic value and their contribution to the antibacterial arts.


SUMMARY OF THE INVENTION

A first embodiment of this invention, therefore, is directed to compounds which inhibit bacterial growth, and salts, prodrugs, and salts of prodrugs thereof, the
 5 compounds having formula (I)



(I),

or formula (II),



(II),

in which

R¹ is hydrogen, -R¹¹, -C(O)OR¹¹, -C(O)NH₂, -C(O)NHR¹², -C(O)NR¹²R¹³, -CH₂R¹⁴, -C(O)OCH₂R¹⁴, -C(O)NHCH₂R¹⁴, or -C(O)N(CH₂R¹⁴)₂;

15 R² is hydrogen or R^P, in which R^P is a hydroxyl protecting moiety;

one of R³ or R⁴ is hydrogen and the other is -OH, -OR^P, -OR¹⁵, -OC(O)R¹⁵, -OC(O)OR¹⁵, -OC(O)NH₂, -OC(O)NHR¹⁶, -OC(O)NR¹⁶R¹⁷, -OCH₂R¹⁸, or -OC(O)OCH₂R¹⁸; or

20 R³ and R⁴ together are =O or -CH₂O-;

R^5 is hydrogen, $-R^{19}$, $-C(O)OR^{19}$, $-C(O)NH_2$, $-C(O)NHR^{20}$, $-C(O)NR^{20}R^{21}$, $-CH_2R^{22}$, $-C(O)OCH_2R^{22}$, $-C(O)NHCH_2R^{22}$, or $-OC(O)N(CH_2R^{22})_2$;

R^6 and R^{10} are independently hydrogen or $-R^{23}$;

5 R^7 is $=O$, $=NOH$, $=NOR^P$, $=NOR^{24}$, or $=NO(CH_2)R^{25}$;

one of R^8 and R^9 is hydrogen, and the other is $-OH$ or $-OR^{32}$; or

R^8 and R^9 together are $=O$;

R^{11} , R^{15} , R^{19} , R^{24} , and R^{26} are independently alkyl,
10 $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, alkyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, $-(CH_2)alkenyl$ substituted with one or two or three substituents independently selected from the group
15 consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, or $-(CH_2)alkynyl$ substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, aryl, heteroaryl, and heterocyclyl;

20 R^{12} , R^{13} , R^{16} , R^{17} , R^{20} , R^{21} , R^{27} , and R^{28} are independently alkyl, cycloalkyl, $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, aryl, heteroaryl, heterocyclyl, alkyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl,
25 $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, $-(CH_2)alkenyl$ substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, or $-(CH_2)alkynyl$ substituted with one substituent selected from the group consisting of

cycloalkyl, aryl, heteroaryl, heterocyclyl, -NH_2 , -NHR^{30} , and $\text{-NR}^{30}\text{R}^{31}$; or

R^{12} and R^{13} together, R^{16} and R^{17} together, R^{20} and R^{21} together, or R^{27} and R^{28} together are independently

5 $\text{C}_3\text{-C}_6\text{-alkylene}$, $\text{C}_5\text{-C}_6\text{-alkylene}$ interrupted with one moiety selected from the group consisting of -O- , -NH- , -N(alkyl)- , -S- , -S(O)- , and $\text{-SO}_2\text{-}$, $\text{C}_3\text{-C}_6\text{-alkylene}$ substituted with one substituent selected from the group consisting of -OH , -O(alkyl) , =O , -NH_2 , -NHR^{30} , and $\text{-NR}^{30}\text{R}^{31}$,
10 or $\text{C}_5\text{-C}_6\text{-alkylene}$ interrupted with one moiety selected from the group consisting of -O- , -NH- , -N(alkyl)- , -S- , -S(O)- , and $\text{-SO}_2\text{-}$ and substituted with one substituent selected from the group consisting of -OH , -O(alkyl) , =O , -NH_2 , -NHR^{30} , and $\text{-NR}^{30}\text{R}^{31}$;

15 R^{14} , R^{18} , R^{22} , R^{25} , and R^{29} are independently alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O- , -NH- , -N(alkyl)- , -S- , -S(O)- , and $\text{-SO}_2\text{-}$ or alkyl interrupted with one or two or three moieties independently selected
20 from the group consisting of -O- , -NH- , -N(alkyl)- , -S- , -S(O)- , and $\text{-SO}_2\text{-}$ and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH , =O , -O(alkyl) , -NH_2 , -NHR^{30} , and $\text{-NR}^{30}\text{R}^{31}$;

25 R^{23} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, alkyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, alkenyl substituted with one or two or three
30 substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and

heterocyclyl, alkynyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, aryl, heteroaryl, and heterocyclyl, alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹, alkenyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkenyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹, alkynyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, or alkynyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹;


R^{30} and R^{31} are independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, cycloalkyl, alkyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NH(alkyl)$, and $-N(alkyl)_2$, $-(CH_2)alkenyl$ substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NH(alkyl)$, and $-N(alkyl)_2$, or $-(CH_2)alkynyl$ substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NH(alkyl)$, and $-N(alkyl)_2$; or

R^{30} and R^{31} together are C_3-C_6 -alkylene, C_5-C_6 -alkylene interrupted with one moiety selected from the group consisting of $-O-$, $-NH-$, $-N(alkyl)-$, $-S-$, $-S(O)-$, and $-SO_2-$, C_3-C_6 -alkylene substituted with one substituent selected from the group consisting of $-OH$, $-O(alkyl)$, $=O$, $-NH_2$, $-NH(alkyl)$, and $-N(alkyl)_2$, or C_5-C_6 -alkylene interrupted with one moiety selected from the group consisting of $-O-$, $-NH-$, $-N(alkyl)-$, $-S-$, $-S(O)-$, and $-SO_2-$ and substituted with one substituent selected from the group consisting of $-OH$, $-O(alkyl)$, $=O$, $-NH_2$, $-NH(alkyl)$, and $-N(alkyl)_2$;

R^{32} is $-R^{26}$, $-C(O)OR^{26}$, $-C(O)NH_2$, $-C(O)NHR^{27}$, $-C(O)NR^{27}R^{28}$, $-CH_2R^{29}$, $-C(O)OCH_2R^{29}$, $-C(O)NHCH_2R^{29}$, or $-C(O)N(CH_2R^{29})_2$; and


X^1 is hydrogen or fluoride.

A second embodiment of this invention is directed to a process for making the compounds having formula (I)-b,



(I)-b,

5 or formula (II)-f,



(II)-f,

and salts, prodrugs, or salts of prodrugs thereof, in which

10 R^1 is hydrogen, $-R^{11}$, $-C(O)OR^{11}$, $-C(O)NH_2$, $-C(O)NHR^{12}$,
 $-C(O)NR^{12}R^{13}$, $-CH_2R^{14}$, $-C(O)OCH_2R^{14}$, $-C(O)NHCH_2R^{14}$,
 or $-C(O)N(CH_2R^{14})_2$;

R^5 is hydrogen, $-R^{19}$, $-C(O)OR^{19}$, $-C(O)NH_2$, $-C(O)NHR^{20}$,
 $-C(O)NR^{20}R^{21}$, $-CH_2R^{22}$, $-C(O)OCH_2R^{22}$, $-C(O)NHCH_2R^{22}$,
 or $-CH_2R^{22}$;

15 R^6 and R^{10} are independently hydrogen or $-R^{23}$;

R^{11} and R^{19} are independently alkyl, $-(CH_2)alkenyl$,
 $-(CH_2)alkynyl$, alkyl substituted with one, two,
 or three substituents independently selected from
 the group consisting of cycloalkyl, halo, aryl,
 20 heteroaryl, and heterocyclyl, $-(CH_2)alkenyl$

substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, or $-(CH_2)alkynyl$ substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, aryl, heteroaryl, and heterocyclyl;

R^{12} , R^{13} , R^{20} , and R^{21} are independently alkyl,

cycloalkyl, $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, aryl, heteroaryl, heterocyclyl, alkyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$,

$-(CH_2)alkenyl$ substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, or $-(CH_2)alkynyl$ substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$; or

R^{12} and R^{13} together, or R^{20} and R^{21} together are

C_3-C_6 -alkylene, C_5-C_6 -alkylene interrupted with one moiety selected from the group consisting of $-O-$, $-NH-$, $-N(alkyl)-$, $-S-$, $-S(O)-$, and $-SO_2-$,

C_3-C_6 -alkylene substituted with one substituent selected from the group consisting of $-OH$, $-O(alkyl)$, $=O$, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, or

C_5-C_6 -alkylene interrupted with one moiety selected from the group consisting of $-O-$, $-NH-$, $-N(alkyl)-$, $-S-$, $-S(O)-$, and $-SO_2-$ and substituted with one substituent selected from

the group consisting of -OH, -O(alkyl), =O, -NH₂,
-NHR³⁰, and -NR³⁰R³¹;

R¹⁴ and R²² are independently alkyl interrupted with

one or two or three moieties independently
selected from the group consisting of -O-, -NH-,
-N(alkyl)-, -S-, -S(O)-, and -SO₂- or alkyl
interrupted with one or two or three moieties
independently selected from the group consisting
of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-
and substituted with one or two or three
substituents independently selected from the
group consisting of cycloalkyl, halo, aryl,
heteroaryl, heterocyclyl, -OH, =O, -O(alkyl),
-NH₂, -NHR³⁰, and -NR³⁰R³¹;

R²³ is alkyl, alkenyl, alkynyl, aryl, heteroaryl,
heterocyclyl, alkyl substituted with one, two, or
three substituents independently selected from
the group consisting of cycloalkyl, halo, aryl,
heteroaryl, and heterocyclyl, alkenyl substituted
with one or two or three substituents
independently selected from the group consisting
of cycloalkyl, halo, aryl, heteroaryl, and
heterocyclyl, alkynyl substituted with one, two,
or three substituents independently selected from
the group consisting of cycloalkyl, aryl,
heteroaryl, and heterocyclyl, alkyl interrupted
with one or two or three moieties independently
selected from the group consisting of -O-, -NH-,
-N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkyl
interrupted with one or two or three moieties
independently selected from the group consisting
of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-

and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹, alkenyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkenyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹, alkynyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, or alkynyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹; and R³⁰ and R³¹ are independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -(CH₂)alkenyl, -(CH₂)alkynyl, cycloalkyl, alkyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl,


heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂,
 -(CH₂)alkenyl substituted with one substituent
 selected from the group consisting of cycloalkyl,
 aryl, heteroaryl, heterocyclyl, -NH₂, -NH(alkyl),
 and -N(alkyl)₂, or -(CH₂)alkynyl substituted with
 one substituent selected from the group
 consisting of cycloalkyl, aryl, heteroaryl,
 heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂;

or

R³⁰ and R³¹ together are C₃-C₆-alkylene, C₅-C₆-alkylene
 interrupted with one moiety selected from the
 group consisting of -O-, -NH-, -N(alkyl)-, -S-,
 -S(O)-, and -SO₂-, C₃-C₆-alkylene substituted with
 one substituent selected from the group
 consisting of -OH, -O(alkyl), =O, -NH₂,
 -NH(alkyl), and -N(alkyl)₂, or C₅-C₆-alkylene
 interrupted with one moiety selected from the
 group consisting of -O-, -NH-, -N(alkyl)-, -S-,
 -S(O)-, and -SO₂- and substituted with one
 substituent selected from the group consisting of
 -OH, -O(alkyl), =O, -NH₂, -NH(alkyl), and
 -N(alkyl)₂;


the process comprising the steps of:

(a) reacting a compound having formula (X)



(X),

or a compound having formula (IX)



(IX),


5 in which R^P is a hydroxyl protecting moiety and R^{P1} is trimethylsilyl or triethylsilyl,

a compound having formula $(X^2CHR^{10}CO)_2O$,

in which X^2 is $-Cl$ or $-Br$,


and a second base, with or without

10 4-(N,N-dimethylamino)pyridine, to provide a compound having formula (XI)



(XI),

or a compound having formula (XIII)




15


(XIII),

respectively;

(b) reacting the product of step (a) and a compound having formula R^5NH_2 to provide a compound having formula (XII)




5 (XII),
or a compound having formula (XIV)



(XIV),


respectively;

10 (c) reacting the product of step (b), a compound having formula R^6CHO , and a first acid, between about 75°C and about 120°C, to provide a compound having formula (I)-a



(I)-a,


15 or a compound having formula (XV)



(XV),

respectively;

- (d) reacting the compound having formula (XV) and a
 5 fluorinating agent and reacting the product obtained
 therefrom and an oxidant, with or without a second base, to
 provide a compound having formula (II)-c




(II)-c;

10 and

- (e)-(1) reacting the compound having formula (I)-a
 and a deprotecting agent,
 or

- (e)-(2) reacting the compound having formula (II)-c
 15 and a deprotecting agent.

A third embodiment of this invention is directed to a
 process for making compounds having formula (II)-g



(II)-g,

or salts, prodrugs, or salts of prodrugs thereof, in which

5 R^1 is hydrogen, $-R^{11}$, $-C(O)OR^{11}$, $-C(O)NH_2$, $-C(O)NHR^{12}$,
 $-C(O)NR^{12}R^{13}$, $-CH_2R^{14}$, $-C(O)OCH_2R^{14}$, $-C(O)NHCH_2R^{14}$,
 or $-C(O)N(CH_2R^{14})_2$;

R^5 is hydrogen, $-R^{19}$, $-C(O)OR^{19}$, $-C(O)NH_2$, $-C(O)NHR^{20}$,
 $-C(O)NR^{20}R^{21}$, $-CH_2R^{22}$, $-C(O)OCH_2R^{22}$, $-C(O)NHCH_2R^{22}$,
 or $-OC(O)N(CH_2R^{22})_2$;

10 R^6 and R^{10} are independently hydrogen or $-R^{23}$;

R^{11} and R^{19} are independently alkyl, $-(CH_2)alkenyl$,
 $-(CH_2)alkynyl$, alkyl substituted with one, two,
 or three substituents independently selected from
 the group consisting of cycloalkyl, halo, aryl,
 15 heteroaryl, and heterocyclyl, $-(CH_2)alkenyl$
 substituted with one or two or three substituents
 independently selected from the group consisting
 of cycloalkyl, halo, aryl, heteroaryl, and
 heterocyclyl, or $-(CH_2)alkynyl$ substituted with
 20 one or two or three substituents independently
 selected from the group consisting of cycloalkyl,
 aryl, heteroaryl, and heterocyclyl;

R^{12} , R^{13} , R^{20} , and R^{21} are independently alkyl,
 cycloalkyl, $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, aryl,
 25 heteroaryl, heterocyclyl, alkyl substituted with
 one substituent selected from the group

consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH_2 , -NHR^{30} , and $\text{-NR}^{30}\text{R}^{31}$,
 $\text{-(CH}_2\text{)alkenyl}$ substituted with one substituent
selected from the group consisting of cycloalkyl,
5 aryl, heteroaryl, heterocyclyl, -NH_2 , -NHR^{30} , and
 $\text{-NR}^{30}\text{R}^{31}$, or $\text{-(CH}_2\text{)alkynyl}$ substituted with one
substituent selected from the group consisting of
cycloalkyl, aryl, heteroaryl, heterocyclyl, -NH_2 ,
 -NHR^{30} , and $\text{-NR}^{30}\text{R}^{31}$; or

10 R^{12} and R^{13} together, or R^{20} and R^{21} together are
 $\text{C}_3\text{-C}_6\text{-alkylene}$, $\text{C}_5\text{-C}_6\text{-alkylene}$ interrupted with one
moiety selected from the group consisting of -O- ,
 -NH- , -N(alkyl)- , -S- , -S(O)- , and $\text{-SO}_2\text{-}$,
 $\text{C}_3\text{-C}_6\text{-alkylene}$ substituted with one substituent
15 selected from the group consisting of -OH ,
 -O(alkyl) , =O , -NH_2 , -NHR^{30} , and $\text{-NR}^{30}\text{R}^{31}$, or
 $\text{C}_5\text{-C}_6\text{-alkylene}$ interrupted with one moiety
selected from the group consisting of -O- , -NH- ,
 -N(alkyl)- , -S- , -S(O)- , and $\text{-SO}_2\text{-}$ and substituted
20 with one substituent selected from the group
consisting of -OH , -O(alkyl) , =O , -NH_2 , -NHR^{30} ,
and $\text{-NR}^{30}\text{R}^{31}$;

R^{14} and R^{22} are independently alkyl interrupted with
one or two or three moieties independently
25 selected from the group consisting of -O- , -NH- ,
 -N(alkyl)- , -S- , -S(O)- , and $\text{-SO}_2\text{-}$ or alkyl
interrupted with one or two or three moieties
independently selected from the group consisting
of -O- , -NH- , -N(alkyl)- , -S- , -S(O)- , and $\text{-SO}_2\text{-}$
30 and substituted with one or two or three

substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹;

5 R²³ is alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, alkyl substituted with one, two, or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, alkenyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, alkynyl substituted with one, two, or three substituents independently selected from the group consisting of cycloalkyl, aryl, heteroaryl, and heterocyclyl, alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹, alkenyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkenyl interrupted with one or two moieties independently selected from the group consisting


of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-
and substituted with one or two or three
substituents independently selected from the
group consisting of cycloalkyl, halo, aryl,
heteroaryl, heterocyclyl, -OH, =O, -O(alkyl),
-NH₂, -NHR³⁰, and -NR³⁰R³¹, alkynyl interrupted
with one or two moieties independently selected
from the group consisting of -O-, -NH-,
-N(alkyl)-, -S-, -S(O)-, and -SO₂-, or alkynyl
interrupted with one or two moieties
independently selected from the group consisting
of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-
and substituted with one or two or three
substituents independently selected from the
group consisting of cycloalkyl, halo, aryl,
heteroaryl, heterocyclyl, -OH, =O, -O(alkyl),
-NH₂, -NHR³⁰, and -NR³⁰R³¹; and
R³⁰ and R³¹ are independently alkyl, cycloalkyl, aryl,
heteroaryl, heterocyclyl, -(CH₂)alkenyl,
-(CH₂)alkynyl, cycloalkyl, alkyl substituted with
one substituent selected from the group
consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂,
-(CH₂)alkenyl substituted with one substituent
selected from the group consisting of cycloalkyl,
aryl, heteroaryl, heterocyclyl, -NH₂, -NH(alkyl),
and -N(alkyl)₂, or -(CH₂)alkynyl substituted with
one substituent selected from the group
consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂;

or

R^{30} and R^{31} together are C_3 - C_6 -alkylene, C_5 - C_6 -alkylene interrupted with one moiety selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, C_3 - C_6 -alkylene substituted with one substituent selected from the group consisting of -OH, -O(alkyl), =O, -NH₂, -NH(alkyl), and -N(alkyl)₂, or C_5 - C_6 -alkylene interrupted with one moiety selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one substituent selected from the group consisting of -OH, -O(alkyl), =O, -NH₂, -NH(alkyl), and -N(alkyl)₂;

the process comprising the steps of:

(a) reacting a compound having formula (II)-c




(II)-c,

in which R^P is a hydroxyl protecting moiety, and a fluorinating agent, with or without a fourth base;

and


(b) reacting the product of step (a) and deprotecting agent.

A fourth embodiment of this invention is directed to compounds employed in the second embodiment, the compounds having formula (XI)




(XI),

formula (XII),




(XII),

formula (XIII),



(XIII),

or formula (XIV),



(XIV),

and salts thereof, in which

R¹ is hydrogen, -R¹¹, -C(O)OR¹¹, -C(O)NH₂, -C(O)NHR¹²,
 5 -C(O)NR¹²R¹³, -CH₂R¹⁴, -C(O)OCH₂R¹⁴, -C(O)NHCH₂R¹⁴, or
 -C(O)N(CH₂R¹⁴)₂;

R⁵ is hydrogen, -R¹⁹, -C(O)OR¹⁹, -C(O)NH₂, -C(O)NHR²⁰,
 -C(O)NR²⁰R²¹, -CH₂R²², -C(O)OCH₂R²², -C(O)NHCH₂R²², or
 -OC(O)N(CH₂R²²)₂;

10 R¹⁰ is hydrogen or -R²³;

R¹¹ and R¹⁹ are independently alkyl, -(CH₂)alkenyl,
 -(CH₂)alkynyl, alkyl substituted with one or two or three
 substituents independently selected from the group
 consisting of cycloalkyl, halo, aryl, heteroaryl, and
 15 heterocyclyl, -(CH₂)alkenyl substituted with one or two or
 three substituents independently selected from the group
 consisting of cycloalkyl, halo, aryl, heteroaryl, and
 heterocyclyl, or -(CH₂)alkynyl substituted with one or two
 or three substituents independently selected from the group
 20 consisting of cycloalkyl, aryl, heteroaryl, and
 heterocyclyl;

R¹², R¹³, R²⁰, and R²¹ are independently alkyl,
 cycloalkyl, -(CH₂)alkenyl, -(CH₂)alkynyl, aryl, heteroaryl,
 heterocyclyl, alkyl substituted with one substituent
 25 selected from the group consisting of cycloalkyl, aryl,
 heteroaryl, heterocyclyl, -NH₂, -NHR³⁰, and -NR³⁰R³¹,

-(CH₂)alkenyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, -NH₂, -NHR³⁰, and -NR³⁰R³¹, or -(CH₂)alkynyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, -NH₂, -NHR³⁰, and -NR³⁰R³¹; or

R¹² and R¹³ together, or R²⁰ and R²¹ together are independently C₃-C₆-alkylene, C₅-C₆-alkylene interrupted with one moiety selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, C₃-C₆-alkylene substituted with one substituent selected from the group consisting of -OH, -O(alkyl), =O, -NH₂, -NHR³⁰, and -NR³⁰R³¹, or C₅-C₆-alkylene interrupted with one moiety selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one substituent selected from the group consisting of -OH, -O(alkyl), =O, -NH₂, -NHR³⁰, and -NR³⁰R³¹;

R¹⁴ and R²² are independently alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- or alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹;

R²³ is alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, alkyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and

heterocyclyl, alkenyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, alkynyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, aryl, heteroaryl, and heterocyclyl, alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹, alkenyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkenyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹, alkynyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, or alkynyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl,

heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰,
and -NR³⁰R³¹;

R³⁰ and R³¹ are independently alkyl, cycloalkyl, aryl,
heteroaryl, heterocyclyl, -(CH₂)alkenyl, -(CH₂)alkynyl,
5 cycloalkyl, alkyl substituted with one substituent selected
from the group consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂,
-(CH₂)alkenyl substituted with one substituent selected
from the group consisting of cycloalkyl, aryl, heteroaryl,
10 heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂, or
-(CH₂)alkynyl substituted with one substituent selected
from the group consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂; or

R³⁰ and R³¹ together are C₃-C₆-alkylene, C₅-C₆-alkylene
15 interrupted with one moiety selected from the group
consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-,
C₃-C₆-alkylene substituted with one substituent selected
from the group consisting of -OH, -O(alkyl), =O, -NH₂,
-NH(alkyl), and -N(alkyl)₂, or C₅-C₆-alkylene interrupted
20 with one moiety selected from the group consisting of -O-,
-NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted
with one substituent selected from the group consisting of
-OH, -O(alkyl), =O, -NH₂, -NH(alkyl), and -N(alkyl)₂;

R^P is (methyl)carbonyl or (phenyl)carbonyl;

25 R^{P1} is trimethylsilyl or triethylsilyl; and

X² is chloride or bromide.

A fifth embodiment of this invention is directed to
compositions which are useful for prophylaxis or treatment
of bacterial infections in a fish or a mammal comprising a

therapeutically effective amount of one or more of the compounds of the first embodiment and an excipient.

A sixth embodiment of this invention is directed to use of the compounds of the first embodiment for preparation of a medicament for prophylaxis or treatment of bacterial
5 infections.

DETAILED DESCRIPTION OF THE INVENTION

Compounds of this invention, also referred to as "the
10 compounds," comprise both fixed and variable moieties, which variable moieties are identified by a capital letter and accompanying numerical and/or alphabetical superscript, and for which the following terms have the meanings indicated.

15 "Alkenyl" means monovalent, straight-chain and branched-chain hydrocarbon moieties, having two to eight carbon atoms and at least one carbon-carbon double bond, attached through a carbon atom.

Examples of alkenyl moieties include but-1,3-dienyl,
20 butenyl, but-2-enyl, ethenyl, 1-ethylhexen-2-yl, hex-3-enyl, 1-methylbutenyl, 2-methylbutenyl, 1-methylbut-2-enyl, 1-methylbut-1,3-dienyl, pentenyl, pent-2-enyl, pent-3-enyl, and propenyl.

"Alkyl" means monovalent, saturated, straight-chain
25 and branched-chain hydrocarbon moieties, having one to six carbon atoms, attached through a carbon atom.

Examples of alkyl moieties include butyl,
1,1,-dimethylethyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl,
ethyl, 1-ethylpropyl, 2-ethylpropyl, hexyl, methyl,
30 2-methylpropyl, 3-methylbutyl, 1-methylpentyl,
2-methylpent-3-yl, and pentyl.

"Alkylene" means divalent, saturated, straight-chain and branched-chain hydrocarbon moieties, having one to eight carbon atoms, attached through carbon atoms.

Examples of alkylene moieties include butylene,
5 1,1,-dimethylethylene, 1,1-dimethylpropylene,
1,2-dimethylpropylene, ethylene, 1-ethylpropylene,
2-ethylpropylene, hexylene, methylene, 2-methylpropylene,
3-methylbutylene, 1-methylpentylene,
2-methyl-2-ethylpropylene, and pentylene.

10 "Alkynyl" means monovalent, straight-chain and branched-chain hydrocarbon moieties, having two to six carbon atoms and at least one carbon-carbon triple bond, attached through a carbon atom.

Examples of alkynyl moieties include ethynyl
15 (acetylenyl), pentynyl, pent-2-ynyl, pent-3-ynyl,
pent-4-ynyl, 1-methylbut-2-ynyl, 2-methylbut-3-ynyl,
hexynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl,
1-methyl-pent-2-ynyl, 1-methylenepent-3-ynyl,
1-methyl-pent-2,4-diynyl, and prop-2-ynyl (propargyl).

20 "Aryl" means monovalent, unsubstituted and substituted phenyl moieties, attached through a carbon atom and unfused or fused with another phenyl moiety or a cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, naphthyl, or saturated part of an indanyl moiety.

25 Examples of phenyl moieties fused with phenyl, naphthyl, or the saturated part of an indanyl moieties are unsubstituted and substituted naphth-(1- or 2- or 3- or 4-)yl, anthracen-(1- or 2- or 3- or 4-)yl, and fluoren-(1- or 2- or 3- or 4-)yl, respectively.

30 Examples of phenyl moieties fused with cycloalkyl moieties are unsubstituted and substituted indan-(4- or 5- or 6- or 7-)yl and 1,2,3,4-tetrahydronaphth-(5- or 6- or 7- or 8-)yl.

Examples of phenyl moieties fused with cycloalkenyl moieties are unsubstituted and substituted inden-(4- or 5- or 6- or 7-)yl, 1,2-dihydronaphth-(5- or 6- or 7- or 8-)yl and 1,2-dihydronaphth-(5- or 6- or 7- or 8-)yl.

5 Examples of phenyl moieties fused with heteroaryl moieties include unsubstituted and substituted benzimidazol-(4- or 5- or 6- or 7-)yl, 1-benzofuran-(4- or 5- or 6- or 7-)yl, 1,2-benzisothiazol-(4- or 5- or 6- or 7-
10 yl, benzthiazol-(4- or 5- or 6- or 7-)yl, 1-benzothiophen-(4- or 5- or 6- or 7-)yl, cinnolin-(5- or 6- or 7- or 8-)yl, indol-(4- or 5- or 6- or 7-)yl, isoquinolin-(5- to 8-)yl, phthalazin-(5- to 8-)yl, quinazolin-(5- to 8-)yl, quinolin-(5- or 6- or 7- or 8-)yl, and quinoxalin-(5- or 6- or 7- or 8-)yl.

15 Examples of phenyl moieties fused with heterocyclyl moieties include unsubstituted and substituted 1,3-benzodiox-(4- or 5- or 6- or 7-)yl, 1,4-benzodiox-(5- or 6- or 7- or 8-)yl, 1,3-dihydro-2-benzofuran-(4- or 5- or 6- or 7-)yl, 2,3-dihydro-1-benzofuran-(4- or 5- or 6- or
20 7-)yl, 1,3-dihydro-2-benzothiophen-(4- or 5- or 6- or 7-)yl, 2,3-dihydro-1-benzothiophen-(4- or 5- or 6- or 7-)yl, and indolin-(4- or 5- or 6- or 7-)yl.

"Cycloalkyl" means monovalent, unsubstituted and substituted, saturated cyclic hydrocarbon moieties, having
25 three to six carbon atoms, attached through a carbon atom.

Examples of cycloalkyl moieties are unsubstituted and substituted cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

"Cycloalkenyl" means means monovalent, unsubstituted
30 and substituted, cyclic hydrocarbon moieties having four to six carbon atoms and at least one carbon-carbon double bond, attached through a carbon atom.

Examples of cycloalkenyl moieties are unsubstituted and substituted 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, cyclohexenyl, cyclopentadienyl, and cyclopentenyl.

"Halo" means fluoro (-F), chloro (-Cl), bromo (-Br),
5 and iodo (-I) moieties.

"Heteroaryl" means (1) monovalent, aromatic, unsubstituted and substituted five-membered ring moieties having two double bonds and (a) one oxygen or one sulfur atom, (b) one, two, three, or four nitrogen atoms, or (c)
10 one or two nitrogen atoms and one oxygen or one sulfur atom, in which, for (a), (b) and (c), the remaining atoms are carbon atoms and the rings themselves may be attached through a carbon atom or a nitrogen atom; and (2) monovalent six-membered ring moieties having three double
15 bonds and one or two or three nitrogen atoms and the remaining atoms are carbon atoms, and the rings themselves are attached through a carbon atom; in which the heteroaryl moieties (1) and (2) are unfused or fused with another heteroaryl moiety or an aryl moiety.

20 Examples of five-membered heteroaryl moieties are unsubstituted and substituted furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, oxazolyl, pyrazolyl, pyrrolyl, tetrazolyl, 1,3,4-thiadiazolyl, thiazolyl, thiophenyl (thienyl), 1H-tetrazolyl,
25 2H-tetraazolyl, and 1,2,3-triazolyl.

Examples of five-membered heteroaryl moieties fused with aryl moieties include unsubstituted and substituted benzimidazol-(1- or 2-)yl, 1-benzofuran-(2- or 3-)yl,
1,2-benzisothiazol-3-yl, benzthiazol-2-yl,
30 1-benzothiophen-(2- or 3-)yl, cinnolin-(3- or 4-)yl, indol-(1- or 2- or 3-)yl, isoquinolin-(1- or 3- or 4-)yl, phthalazin-(1- or 4-)yl, quinazolin-(2- or 4-)yl, quinolin-(2- or 3- or 4-)yl, and quinoxalin-(2- or 3-)yl.

Examples of five-membered heteroaryl moieties fused with other five-membered heteroaryl moieties include unsubstituted and substituted

(1,3)thiazolo(4,5-d)(1,3)oxazolyl,

5 (1,3)thiazolo(4,5-d)(1,3)thiazolyl,

thieno(3,2-d)(1,3)oxazolyl, thieno(3,2-d)(1,3)thiazolyl,

and thieno(2,3-b)thiophenyl.

Examples of five-membered heteroaryl moieties fused with six-membered heteroaryl moieties include unsubstituted

10 and substituted furo(2,3-b)pyridin-(2- or 3-)yl,

3H-imidazo(4,5-b)pyridin-(2- or 3-)yl,

(1,3)thiazolo(4,5-b)pyrazin-2-yl,

(1,3)thiazolo(4,5-b)pyridin-2-yl, and thieno(2,3-b)pyridin-(2- or 3-)yl.

15 Examples of six-membered heteroaryl moieties are unsubstituted and substituted pyrazinyl, pyridazinyl, pyridyl, pyrimidinyl, and 1,3,5-triazinyl.

Six-membered heteroaryl moieties fused with aryl moieties include unsubstituted and substituted cinnolin-(3- or 4-)yl, isoquinolin-(1- or 3- or 4-)yl, phthalazin-(1- or 20 4-)yl, quinazolin-(2- or 4-)yl, quinolin-(2- or 3- or 4-)yl, and quinoxalin-(2- or 3-)yl.

Six-membered heteroaryl moieties fused with five-membered heteroaryl moieties include unsubstituted and 25 substituted furo(2,3-b)pyridin-(4- or 5- or 6-)yl, 3H-imidazo(4,5-b)pyridin-(5- or 6- or 7-)yl, (1,3)thiazolo(4,5-b)pyrazin-(5- or 6-)yl, (1,3)thiazolo(4,5-b)pyridin-(5- or 6- or 7-)yl, and thieno(2,3-b)pyridin-(4- or 5- or 6-)yl.

30 Six-membered heteroaryl moieties fused with other six-membered heteroaryl moieties include unsubstituted and substituted 1,5-naphthyridinyl, 1,7-naphthyridinyl, 1,8-naphthyridinyl, pteridinyl,

pyridazino(4,5-d)pyridazinyl, pyrido(2,3-d)pyridazinyl, and pyrido(3,4-d)pyridazinyl.

"Heterocyclyl" means (a) monovalent, non-aromatic, unsubstituted and substituted four-membered ring moieties having one nitrogen, oxygen, or sulfur atom and the remaining atoms are carbon atoms, zero double bonds, attached through a carbon atom or a nitrogen atom, (b) monovalent, non-aromatic, unsubstituted and substituted five-membered ring moieties having one or two nitrogen, oxygen, or sulfur atoms and the remaining atoms are carbon atoms, and zero or one double bonds, attached through a carbon atom or a nitrogen atom, and (c) monovalent, non-aromatic, unsubstituted and substituted six-membered ring moieties having one or two or three nitrogen, oxygen, or sulfur atoms and the remaining atoms are carbon atoms, and zero, one, or two double bonds, attached through a carbon atom or a nitrogen atom.

Examples of four-membered heterocyclyl moieties are unsubstituted and substituted oxetane, thietane, and azetidine.

Examples of five-membered heterocyclyl moieties include unsubstituted and substituted 1,4-dioxanyl, 1,3-dioxolanyl, imidazolidinyl, 2-imidazolinyl, 4,5-dihydroisoxazolyl, pyrazolidinyl, 2-pyrazolinyl, pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, and 2H-pyrrolyl.

Examples of six-membered heterocyclyl moieties include unsubstituted and substituted 1,3-dithianyl, 1,4-dithianyl, morpholinyl, piperidinyl, piperazinyl, pyranyl, 2H-pyranyl, 4H-pyranyl, and thiomorpholinyl.

Substituted aryl and heteroaryl moieties are those moieties substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, halo,

-CN, -OH, -SH, -NH₂, -NO₂, -CF₃, -CH₂CF₃, -CF₂CF₃, -OCF₃,
-OCH₂CF₃, -OCF₂CF₃, -OR³⁰, -SR³⁰, -S(O)(alkyl), -SO₂(alkyl),
-C(O)H, -C(O)(alkyl), -C(O)OH, -C(O)O(alkyl), -NH(alkyl),
-N(alkyl)₂, -C(O)NH₂, -C(O)NH(alkyl), -C(O)N(alkyl)₂,
5 -OC(O)(alkyl), -OC(O)O(alkyl), -OC(O)NH₂, -OC(O)NH(alkyl),
-OC(O)N(alkyl)₂, -NHC(O)H, -NHC(O)(alkyl), -NHC(O)O(alkyl),
-NHC(O)NH₂, -NHC(O)NH(alkyl), -NHC(O)N(alkyl)₂, -SO₂NH₂,
-SO₂NH(alkyl), -SO₂N(alkyl)₂, and R⁴⁰, in which R³⁰ is alkyl
or alkyl substituted with one substituent selected from the
10 group consisting of halo, -O(alkyl), and -S(alkyl), and R⁴⁰
is furyl, imidazolyl, indazolidinyl, isoquinolinyl,
isothiazolyl, isoxazolyl, morpholinyl, naphthyl,
naphthyridyl, 1,2,3-oxadiazolyl, oxazolyl, phenyl,
piperidinyl, piperazinyl, pyrazinyl, pyrazolyl, pyridyl,
15 pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolyl,
quinolinyl, quinoxalyl, tetrazolyl, 1,2,3-thiadiazolyl,
1,3,4-thiadiazolyl, thiazolyl, thienyl, 1,2,3-triazolyl, or
thiomorpholinyl, in which each R⁴⁰ moiety is unsubstituted
or substituted with one or two or three substituents
20 independently selected from the group consisting of alkyl,
alkenyl, alkynyl, cycloalkyl, halo, =O, -CN, -OH, -SH,
-NO₂, -CF₃, -CH₂CF₃, -CF₂CF₃, -OCF₃, -OCH₂CF₃, -OCF₂CF₃,
-O(alkyl), -S(alkyl), -S(O)(alkyl), -SO₂(alkyl), -C(O)H,
-C(O)(alkyl), -C(O)OH, -C(O)O(alkyl), -NH₂, -NH(alkyl),
25 -N(alkyl)₂, -C(O)NH₂, -C(O)NH(alkyl), -C(O)N(alkyl)₂,
-OC(O)(alkyl), -OC(O)O(alkyl), -OC(O)NH₂, -OC(O)NH(alkyl),
-OC(O)N(alkyl)₂, -NHC(O)H, -NHC(O)(alkyl), -NHC(O)O(alkyl),
-NHC(O)NH₂, -NHC(O)NH(alkyl), -NHC(O)N(alkyl)₂, -SO₂NH₂,
-SO₂NH(alkyl), and -SO₂N(alkyl)₂.

Substituted cycloalkyl, cycloalkenyl, and heterocyclyl moieties are those moieties substituted with one or two or three substituents independently selected from the group consisting of alkyl, phenyl, halo, -CN, -OH, -NH₂, -CF₃,
5 -OR³⁰, -SR³⁰, -S(O)(alkyl), -SO₂(alkyl), -C(O)H, -C(O)(alkyl), -C(O)OH, -C(O)O(alkyl), -NH(alkyl), -N(alkyl)₂, -C(O)NH₂, -C(O)NH(alkyl), and -C(O)N(alkyl)₂, in which the phenyl is unsubstituted or substituted with one or two or three substituents independently selected from
10 the group consisting of halo, -CN, -OH, -NH₂, and -CF₃.

"Hydroxyl protecting moiety" means selectively introducible and removable moieties which protect -OH moieties against undesirable side reactions. Hydroxyl protecting protecting moieties include
15 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, tert-butoxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-tribromoethoxycarbonyl, 2-(trimethylsilyl)-ethoxycarbonyl,
20 2-(phenylsulfonyl)ethoxycarbonyl, allyloxycarbonyl, acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, pivaloyl, propionyl, 2-methylpropionyl, benzoyl, tert-butyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl,
25 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, para-methoxybenzyl, 3,4-dimethoxybenzyl, diphenylmethyl, triphenylmethyl, tetrahydrofuryl, benzyloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)-ethoxymethyl, methanesulfonyl,
30 para-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, diethylisopropylsilyl, tert-butyl dimethylsilyl, tert-butyl diphenylsilyl, diphenylmethylsilyl, and tert-butyl methoxyphenylsilyl.

These variable moieties may combine to provide a seventh embodiment of this invention, which embodiment is directed to compounds having formula (I) or formula (II), and pharmaceutically acceptable salts, prodrugs, and salts of prodrugs thereof, in which

R^1 is hydrogen, $-R^{11}$, $-C(O)OR^{11}$, $-C(O)NH_2$, $-C(O)NHR^{12}$, or $-C(O)NR^{12}R^{13}$;

R^2 is hydrogen or R^P , in which R^P is a hydroxyl protecting moiety;

one of R^3 or R^4 is hydrogen and the other is $-OH$, $-OR^P$, $-OR^{15}$, $-OC(O)R^{15}$, $-OC(O)OR^{15}$, $-OC(O)NH_2$, $-OC(O)NHR^{16}$, or $-OC(O)NR^{16}R^{17}$; or

R^3 and R^4 together are $=O$ or $-CH_2O-$;

R^5 is hydrogen, $-R^{19}$, $-C(O)OR^{19}$, $-C(O)NH_2$, $-C(O)NHR^{20}$, or $-C(O)NR^{20}R^{21}$;

R^6 and R^{10} are independently hydrogen or $-R^{23}$;

R^7 is $=O$, $=NOH$, $=NOR^P$, or $=NOR^{24}$;

one of R^8 and R^9 is hydrogen, and the other is $-OH$ or $-OR^{32}$; or

R^8 and R^9 together are $=O$;

R^{11} , R^{15} , R^{19} , R^{24} , and R^{26} are independently alkyl,

$-(CH_2)alkenyl$, $-(CH_2)alkynyl$, alkyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, $-(CH_2)alkenyl$ substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, or $-(CH_2)alkynyl$ substituted with one or two or three substituents independently selected from the group

consisting of cycloalkyl, aryl, heteroaryl, and heterocyclyl;

R^{12} , R^{13} , R^{16} , R^{17} , R^{20} , R^{21} , R^{27} , and R^{28} are independently alkyl, cycloalkyl, $-(CH_2)alkenyl$,

5 $-(CH_2)alkynyl$, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, $-(CH_2)alkenyl$ substituted with one substituent selected from the group
10 consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, or $-(CH_2)alkynyl$ substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$;

15 R^{23} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, alkyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, alkenyl substituted with one or two or three
20 substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, or alkynyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, aryl, heteroaryl, and
25 heterocyclyl;

R^{30} and R^{31} are independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, cycloalkyl, alkyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NH(alkyl)$, and $-N(alkyl)_2$,
30 $-(CH_2)alkenyl$ substituted with one substituent selected

from the group consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, $-\text{NH}_2$, $-\text{NH}(\text{alkyl})$, and $-\text{N}(\text{alkyl})_2$, or
 $-(\text{CH}_2)\text{alkynyl}$ substituted with one substituent selected
from the group consisting of cycloalkyl, aryl, heteroaryl,
5 heterocyclyl, $-\text{NH}_2$, $-\text{NH}(\text{alkyl})$, and $-\text{N}(\text{alkyl})_2$;

R^{32} is $-\text{R}^{26}$, $-\text{C}(\text{O})\text{OR}^{26}$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{C}(\text{O})\text{NHR}^{27}$, or
 $-\text{C}(\text{O})\text{NR}^{27}\text{R}^{28}$; and

X^1 is hydrogen or fluoride;

compounds having formula (I) or formula (II), and
10 pharmaceutically acceptable salts, prodrugs, and salts of
prodrugs thereof, in which

R^1 is hydrogen, $-\text{R}^{11}$, $-\text{C}(\text{O})\text{OR}^{11}$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{C}(\text{O})\text{NHR}^{12}$,
or $-\text{C}(\text{O})\text{NR}^{12}\text{R}^{13}$;

R^2 is hydrogen or R^{P} , in which R^{P} is a hydroxyl
15 protecting moiety;

one of R^3 or R^4 is hydrogen and the other is $-\text{OH}$, $-\text{OR}^{\text{P}}$,
or $-\text{OC}(\text{O})\text{R}^{15}$; or

R^3 and R^4 together are $=\text{O}$ or $-\text{CH}_2\text{O}-$;

R^5 is hydrogen, $-\text{R}^{19}$, $-\text{C}(\text{O})\text{OR}^{19}$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{C}(\text{O})\text{NHR}^{20}$,
20 or $-\text{C}(\text{O})\text{NR}^{20}\text{R}^{21}$;

R^6 and R^{10} are independently hydrogen or $-\text{R}^{23}$;

R^7 is $=\text{O}$, $=\text{NOH}$, $=\text{NOR}^{\text{P}}$, or $=\text{NOR}^{24}$;

one of R^8 and R^9 is hydrogen, and the other is $-\text{OH}$ or
 $-\text{OR}^{32}$; or

25 R^8 and R^9 together are $=\text{O}$;

R^{11} , R^{15} , R^{19} , R^{24} , and R^{26} are independently alkyl,
 $-(\text{CH}_2)\text{alkenyl}$, $-(\text{CH}_2)\text{alkynyl}$, alkyl substituted with one or
two or three substituents independently selected from the
group consisting of cycloalkyl, halo, aryl, heteroaryl, and
30 heterocyclyl, $-(\text{CH}_2)\text{alkenyl}$ substituted with one or two or

three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, or $-(CH_2)alkynyl$ substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, aryl, heteroaryl, and heterocyclyl;

R^{12} , R^{13} , R^{20} , R^{21} , R^{27} , and R^{28} are independently alkyl, cycloalkyl, $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, $-(CH_2)alkenyl$ substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, or $-(CH_2)alkynyl$ substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$;

R^{23} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, alkyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, alkenyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, or alkynyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, aryl, heteroaryl, and heterocyclyl;

R^{30} and R^{31} are independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, cycloalkyl, alkyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl,

heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂,
-(CH₂)alkenyl substituted with one substituent selected
from the group consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂, or
5 -(CH₂)alkynyl substituted with one substituent selected
from the group consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂;

R³² is -R²⁶, -C(O)OR²⁶, -C(O)NH₂, -C(O)NHR²⁷, or
-C(O)NR²⁷R²⁸; and

10 X¹ is hydrogen or fluoride;

compounds having formula (I) or formula (II), and
pharmaceutically acceptable salts, prodrugs, and salts of
prodrugs thereof, in which R¹ is methyl, ethyl,
prop-2-ynyl, or prop-2-enyl, each of which is unsubstituted
15 or substituted with one substituent selected from the group
consisting of phenyl, quinolinyl, isoquinolinyl,
quinazolinyl, and quinoxalinyl in which each substituent
is unsubstituted or substituted with one or two
substituents independently selected from the group
20 consisting of -F, -Cl, -Br, -I and -NO₂; R² is hydrogen; R³
is -OH, ((phenyl)carbonyl)oxy, ((methyl)carbonyl)oxy,
(trimethylsilyl)oxy, or (triethylsilyl)oxy and R⁴ is
hydrogen, or R³ and R⁴ together are =O or -CH₂O-; R⁵ is
hydrogen, methyl, ethyl, propyl, prop-2-ynyl, prop-2-enyl,
25 phenylmethyl, 4-methoxyphenylmethyl or
2,4-dimethoxyphenylmethyl; R⁶ is hydrogen, methyl, ethyl,
ethynyl, or phenyl; R⁷ is =O; R⁸ is hydrogen and R⁹ is -OH,
or R⁸ and R⁹ together are =O; R¹⁰ is hydrogen, methyl,
ethyl, prop-2-ynyl or prop-2-enyl; and X¹ is hydrogen or
30 fluoride;

compounds having formula (I) or formula (II), and pharmaceutically acceptable salts, prodrugs, and salts of prodrugs thereof, in which R¹ is prop-2-ynyl substituted with isoxazolyl, in which the isoxazolyl is substituted with one substituent selected from the group consisting of furyl, imidazolyl, isoquinolinyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, oxazolyl, pyridyl, pyrimidinyl, quinolinyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl, and 1,2,3-triazolyl, in which each substituent is unsubstituted or substituted with one or two substituents independently selected from the group consisting of -F, -Cl, -Br, -I and -NO₂; R² is hydrogen; R³ is -OH, ((phenyl)carbonyl)oxy, ((methyl)carbonyl)oxy, (trimethylsilyl)oxy, or (triethylsilyl)oxy and R⁴ is hydrogen, or R³ and R⁴ together are =O or -CH₂O-; R⁵ is hydrogen, methyl, ethyl, propyl, prop-2-ynyl, prop-2-enyl, phenylmethyl, 4-methoxyphenylmethyl, or 2,4-dimethoxyphenylmethyl; R⁶ is hydrogen, methyl, ethyl, ethenyl, or phenyl; R⁷ is =O; R⁸ is hydrogen and R⁹ is -OH, or R⁸ and R⁹ together are =O; R¹⁰ is hydrogen, methyl, ethyl, prop-2-ynyl or prop-2-enyl; and X¹ is hydrogen or fluoride;

compounds having formula (I) or formula (II), and pharmaceutically acceptable salts, prodrugs, and salts of prodrugs thereof, in which R¹ is prop-2-ynyl substituted with thienyl, in which the thienyl is substituted with one substituent selected from the group consisting of furyl, imidazolyl, isoquinolinyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, oxazolyl, pyridyl, pyrimidinyl, quinolinyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl, and

1,2,3-triazolyl, in which each substituent is unsubstituted or substituted with one or two substituents independently selected from the group consisting of -F, -Cl, -Br, -I and -NO₂; R² is hydrogen; R³ is -OH, ((phenyl)carbonyl)oxy, ((methyl)carbonyl)oxy, (trimethylsilyl)oxy, or (triethylsilyl)oxy and R⁴ is hydrogen, or R³ and R⁴ together are =O or -CH₂O-; R⁵ is hydrogen, methyl, ethyl, propyl, prop-2-ynyl, prop-2-enyl, phenylmethyl, 4-methoxyphenylmethyl, or 2,4-dimethoxyphenylmethyl; R⁶ is hydrogen, methyl, ethyl, ethenyl, or phenyl; R⁷ is =O; R⁸ is hydrogen and R⁹ is -OH, or R⁸ and R⁹ together are =O; R¹⁰ is hydrogen, methyl, ethyl, prop-2-ynyl or prop-2-enyl; and X¹ is hydrogen or fluoride;

compounds having formula (I) or formula (II), and pharmaceutically acceptable salts, prodrugs, and salts of prodrugs thereof, in which R¹ is prop-2-enyl substituted with isoxazolyl, in which the isoxazolyl is substituted with one substituent selected from the group consisting of furyl, imidazolyl, isoquinolinyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, oxazolyl, pyridyl, pyrimidinyl, quinolinyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl, and 1,2,3-triazolyl, in which each substituent is unsubstituted or substituted with one or two substituents independently selected from the group consisting of -F, -Cl, -Br, -I and -NO₂; R² is hydrogen; R³ is -OH, ((phenyl)carbonyl)oxy, ((methyl)carbonyl)oxy, (trimethylsilyl)oxy, or (triethylsilyl)oxy and R⁴ is hydrogen, or R³ and R⁴ together are =O or -CH₂O-; R⁵ is hydrogen, methyl, ethyl, propyl, prop-2-ynyl, prop-2-enyl, phenylmethyl, 4-methoxyphenylmethyl, or

2,4-dimethoxyphenylmethyl; R^6 is hydrogen, methyl, ethyl, ethenyl, or phenyl; R^7 is =O; R^8 is hydrogen and R^9 is -OH, or R^8 and R^9 together are =O; R^{10} is hydrogen, methyl, ethyl, prop-2-ynyl or prop-2-enyl; and X^1 is hydrogen or
5 fluoride;

compounds having formula (I) or formula (II), and pharmaceutically acceptable salts, prodrugs, and salts of prodrugs thereof, in which R^1 is prop-2-enyl substituted with thienyl, in which the thienyl is substituted with one
10 substituent selected from the group consisting of furyl, imidazolyl, isoquinolinyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, oxazolyl, pyridyl, pyrimidinyl, quinolinyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl, and
15 1,2,3-triazolyl, in which each substituent is unsubstituted or substituted with one or two substituents independently selected from the group consisting of -F, -Cl, -Br, -I and -NO₂; R^2 is hydrogen; R^3 is -OH, ((phenyl)carbonyl)oxy, ((methyl)carbonyl)oxy,
20 (trimethylsilyl)oxy, or (triethylsilyl)oxy and R^4 is hydrogen, or R^3 and R^4 together are =O or -CH₂O-; R^5 is hydrogen, methyl, ethyl, propyl, prop-2-ynyl, prop-2-enyl, phenylmethyl, 4-methoxyphenylmethyl, or
2,4-dimethoxyphenylmethyl; R^6 is hydrogen, methyl, ethyl, ethenyl, or phenyl; R^7 is =O; R^8 is hydrogen and R^9 is -OH, or R^8 and R^9 together are =O; R^{10} is hydrogen, methyl, ethyl, prop-2-ynyl or prop-2-enyl; and X^1 is hydrogen or
25 fluoride;
and

30 compounds having formula (I) or formula (II), and pharmaceutically acceptable salts, prodrugs, and salts of

prodrugs thereof, in which R¹ is methyl, prop-2-ynyl,
3-(5-pyridin-2-ylthien-2-yl)prop-2-ynyl ,
3-(quinolin-3-yl)prop-2-enyl,
3-(3-pyridin-2-ylisoxazol-5-yl)prop-2-ynyl, or
5 3-(5-pyrimidin-2-ylthien-2-yl)prop-2-ynyl; R² is hydrogen;
R³ is -OH, ((phenyl)carbonyl)oxy, ((methyl)carbonyl)oxy,
(trimethylsilyl)oxy, or (triethylsilyl)oxy and R⁴ is
hydrogen, or R³ and R⁴ together are =O or -CH₂O-; R⁵ is
hydrogen, methyl, ethyl, propyl, prop-2-ynyl, prop-2-enyl,
10 phenylmethyl, 4-methoxyphenylmethyl, or
2,4-dimethoxyphenylmethyl; R⁶ is hydrogen, methyl, ethyl,
ethenyl, or phenyl; R⁷ is =O; R⁸ is hydrogen and R⁹ is -OH,
or R⁸ and R⁹ together are =O; R¹⁰ is hydrogen, methyl,
ethyl, prop-2-ynyl or prop-2-enyl; and X¹ is hydrogen or
15 fluoride.

Specific examples of R¹ moieties for the practice of
this invention are methyl, prop-2-ynyl, and
3-(5-pyridin-2-ylthien-2-yl)prop-2-ynyl.

20 A specific example of a R² moiety for the practice of
this invention is hydrogen.

A specific example of a R³ moiety for the practice of
this invention is ((phenyl)carbonyl)oxy.

A specific example of a R⁴ moiety for the practice of
this invention is hydrogen.

25 Specific examples of R⁵ moieties for the practice of
this invention are hydrogen and methyl.

A specific example of a R⁶ moiety for the practice of
this invention is hydrogen.

30 A specific example of a R⁷ moiety for the practice of
this invention is =O.

A specific example of R^8 and R^9 moieties for the practice of this invention is R^8 and R^9 together are =O.

A specific example of a R^{10} moiety for the practice of this invention is hydrogen.

5 A specific example of a X^1 moiety for the practice of this invention is hydrogen.

These specific moieties may combine to provide an eighth embodiment of this invention, which embodiment is directed to compounds having formula (I) or formula (II),
10 and pharmaceutically acceptable salts, prodrugs, or salts of prodrugs thereof, in which R^1 is alkyl, $-(CH_2)alkynyl$, or $-(CH_2)alkynyl$ substituted with thienyl, in which the thienyl is substituted with pyridyl; R^2 is hydrogen; R^3 is ((phenyl)carbonyl)oxy; R^4 is hydrogen; R^5 is hydrogen or
15 alkyl; R^6 is hydrogen; R^7 is =O; R^8 and R^9 together are =O; R^{10} is hydrogen; and X^1 is hydrogen;

compounds having formula (I) or formula (II), and pharmaceutically acceptable salts, prodrugs, or salts of prodrugs thereof, in which R^1 is methyl, prop-2-ynyl or
20 prop-2-ynyl substituted with thienyl, in which the thienyl is substituted with pyridyl; R^2 is hydrogen; R^3 is ((phenyl)carbonyl)oxy; R^4 is hydrogen; R^5 is hydrogen or methyl; R^6 is hydrogen; R^7 is =O; R^8 and R^9 together are =O; R^{10} is hydrogen; and X^1 is hydrogen;

25 compounds having formula (I) or formula (II), and pharmaceutically acceptable salts, prodrugs, and salts of prodrugs thereof, in which R^1 is methyl; R^2 is hydrogen; R^3 is ((phenyl)carbonyl)oxy; R^4 is hydrogen; R^5 is hydrogen or methyl; R^6 is hydrogen; R^7 is =O; R^8 and R^9 together are =O;
30 R^{10} is hydrogen; and X^1 is hydrogen;

compounds having formula (I) or formula (II), and pharmaceutically acceptable salts, prodrugs, and salts of prodrugs thereof, in which R¹ is prop-2-ynyl; R² is hydrogen; R³ is ((phenyl)carbonyl)oxy; R⁴ is hydrogen; R⁵ is hydrogen or methyl; R⁶ is hydrogen; R⁷ is =O; R⁸ and R⁹ together are =O; R¹⁰ is hydrogen; and X¹ is hydrogen;

compounds having formula (I) or formula (II), and pharmaceutically acceptable salts, prodrugs, or salts of prodrugs thereof, in which R¹ is 3-(5-pyridin-2-ylthien-2-yl)prop-2-ynyl; R² is hydrogen; R³ is ((phenyl)carbonyl)oxy; R⁴ is hydrogen; R⁵ is hydrogen or methyl; R⁶ is hydrogen; R⁷ is =O; R⁸ and R⁹ together are =O; R¹⁰ is hydrogen; and X¹ is hydrogen; and

compounds, and pharmaceutically acceptable salts, prodrugs, and salts of prodrugs thereof, which are (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-12-fluoro-8-methoxy-3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxohexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca-(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-ethyl-8-methoxy-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxohexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca-(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-ethyl-12-fluoro-8-methoxy-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxohexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-8-methoxy-3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 13-trioxo-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl) oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd) pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-3-allyl-15-ethyl-8-methoxy-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 13-trioxo-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl) oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd) pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-8-methoxy-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 13-trioxo-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl) oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd) pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-12-fluoro-8-methoxy-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 11, 13-tetraoxohexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd) pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-12-fluoro-3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 11, 13-tetraoxo-8-(prop-2-ynyloxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd) pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-3-allyl-15-ethyl-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 11, 13-tetraoxo-8-(prop-2-ynyloxy) hexadecahydro-2H-1, 14-dioxo-3-

azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-ethyl-12-fluoro-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-(prop-2-ynyloxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-12-fluoro-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-(prop-2-ynyloxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-(prop-2-ynyloxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-3,4a,6,8,10,12,15a-heptamethyl-2,5,13-trioxo-8-(prop-2-ynyloxy)-9-((3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,13-trioxo-8-(prop-2-ynyloxy)-9-((3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,13-trioxo-8-(prop-2-ynyloxy)-9-((3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-

hexopyranosyl) oxy) hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca (1,2,3-cd) pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-12-fluoro-3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-
 5 ((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy) hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca
 (1,2,3-cd) pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

10 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy) hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca (1,2,3-cd) pentalen-9-yl
 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

15 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-ethyl-12-fluoro-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy) hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca
 (1,2,3-cd) pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -
 20 D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy) hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca (1,2,3-cd) pentalen-9-yl 3,4,6-
 25 trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-12-fluoro-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-
 ((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy) hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca
 30 (1,2,3-cd) pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -15-ethyl-3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 13-trioxo-8-((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy)-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -3-allyl-15-ethyl-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 13-trioxo-8-((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy)-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -15-ethyl-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 13-trioxo-8-((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy)-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -15-ethyl-3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 11, 13-tetraoxo-8-((3-(5-pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -15-ethyl-12-fluoro-3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 11, 13-tetraoxo-8-((3-(5-pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-3-allyl-15-ethyl-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 11, 13-tetraoxo-8-((3-(5-pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy)hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca

5 (1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-3-allyl-15-ethyl-12-fluoro-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 11, 13-tetraoxo-8-((3-(5-pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy)hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca-
10 (1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 11, 13-tetraoxo-8-((3-(5-pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy)hexadecahydro-2H-
15 1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

29 (2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-12-fluoro-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 11, 13-tetraoxo-8-
20 ((3-(5-pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy)-hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-
25 3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 13-trioxo-8-((3-(5-pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy)-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)-hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl-
30 α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-3-allyl-15-ethyl-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 13-trioxo-8-((3-(5-

- pyrimidin-2-ylthien-2-yl)prop-2-ynyl oxy)-9-((3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-
- 5 α -L-ribo-hexopyranoside;
 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,13-trioxo-8-((3-(5-pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy)-9-((3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)
- 10 hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;
 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-((3-(3-pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)hexadecahydro-2H-
- 15 1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;
 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-12-fluoro-3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-
- 20 ((3-(3-pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;
 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-
- 25 ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-((3-(3-pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;
 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-
- 30 ethyl-12-fluoro-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-((3-(3-pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca

(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-((3-(3-pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-12-fluoro-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-((3-(3-pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-3,4a,6,8,10,12,15a-heptamethyl-2,5,13-trioxo-8-((3-(3-pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)-9-((3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)-hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)-pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,13-trioxo-8-((3-(3-pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)-9-((3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)-hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)-pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,13-trioxo-8-((3-(3-pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)-9-((3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)hexadecahydro-2H-

1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-(((2E)-3-quinolin-3-ylprop-2-enyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-12-fluoro-3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-(((2E)-3-quinolin-3-ylprop-2-enyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-3-allyl-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-(((2E)-3-quinolin-3-ylprop-2-enyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-3-allyl-15-ethyl-12-fluoro-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-(((2E)-3-quinolin-3-ylprop-2-enyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-(((2E)-3-quinolin-3-ylprop-2-enyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-12-fluoro-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-(((2E)-3-quinolin-3-ylprop-2-enyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 13-trioxo-8-((2E)-3-quinolin-3-ylprop-2-enyl)oxy)-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca(1, 2, 3-cd)pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-3-allyl-15-ethyl-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 13-trioxo-8-((2E)-3-quinolin-3-ylprop-2-enyl)oxy)-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca(1, 2, 3-cd)pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 13-trioxo-8-((2E)-3-quinolin-3-ylprop-2-enyl)oxy)-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca(1, 2, 3-cd)pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 11, 13-tetraoxo-8-((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy)hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca(1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-8-methoxy-3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 11, 13-tetraoxohexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca(1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aS, 4aR, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bR)-15-ethyl-8-methoxy-3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 11, 13-tetraoxohexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca-

(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10S,11S,12R,15R,15aS,15bS)-15-ethyl-3,4a,6,8,10,12,15a-heptamethyl-2,5,13-trioxo-8-(prop-2-ynyloxy)-9-((3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-11-yl 4-O-benzoyl-2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-(prop-2-ynyloxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside; and

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-8-methoxy-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxohexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside.

Compounds of this invention contain asymmetrically substituted carbon atoms in the R or S configuration, in which the terms "R" and "S" are as defined by the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-10.

Compounds having asymmetrically substituted carbon atoms with equal amounts of R and S configurations are racemic at those carbon atoms. Atoms with an excess of one configuration over the other are assigned the configuration which is present in the higher amount, preferably an excess of about 85%-90%, more preferably an excess of about 95%-99%, and still more preferably an excess greater than about 99%. Accordingly, this invention is meant to embrace all stereoisomers of the compounds including racemic

mixtures, enantiomers, mixtures of enantiomers, diastereomers, and mixtures of diastereomers.

Individual stereoisomers of the compounds may be prepared by any one of a number of methods within the knowledge of the ordinarily skilled practitioner. These methods include stereospecific synthesis, chromatographic separation of diastereomers, chromatographic resolution of enantiomers, enzymatic resolution, and conversion of enantiomers in an enantiomeric mixture to diastereomers and chromatographically separating the diastereomers and regeneration of the individual enantiomers.

Stereospecific synthesis involves the use of appropriate chiral starting materials and synthetic reactions which do not cause racemization or inversion of stereochemistry at the chiral centers.

Diastereomeric mixtures of compounds resulting from a synthetic reaction can be separated by chromatographic techniques which are well-known to the ordinarily skilled practitioner.

Chromatographic resolution of enantiomers can be accomplished on chiral commercially available chromatography resins. In practice, the racemate is placed in solution and loaded onto the column containing a chiral stationary phase. The enantiomers are then separated by high performance liquid chromatography.

Enzymes, such as esterases, phosphatases and lipases, may be useful for resolution of derivatives of the enantiomers in an enantiomeric mixture. For example, an ester derivative of a carboxyl group of the compounds to be separated can be prepared. Certain enzymes will selectively hydrolyze only one of the enantiomers in the mixture. Then the resulting enantiomerically pure acid can be separated from the unhydrolyzed ester.

Resolution of enantiomers may also be accomplished by converting the enantiomers in the mixture to diastereomers by reacting of the former and chiral auxiliaries. The

resulting diastereomers can then be separated by column chromatography. This technique is especially useful when the compounds to be separated contain a carboxyl, amino or hydroxyl group that will form a salt or covalent bond with the chiral auxiliary. Chirally pure amino acids, organic carboxylic acids or organosulfonic acids are especially useful as chiral auxiliaries. Once the diastereomers have been separated by chromatography, the individual enantiomers can be regenerated. Frequently, the chiral auxiliary can be recovered and reused.

Compounds of this invention may also contain carbon-carbon double bonds in the Z or E configuration, in which the term "Z" represents the larger two substituents on the same side of a carbon-carbon double bond and the term "E" represents the larger two substituents on opposite sides of a carbon-carbon double bond. The compounds may also exist as an equilibrium mixture of Z or E configurations.

Compounds of this invention which contain hydroxyl, amino, or carboxylic acids may have attached thereto prodrug-forming moieties. The prodrug-forming moieties are removed by metabolic processes and release the compounds having the freed hydroxyl, amino, or carboxylic acid in vivo. Prodrugs are useful for adjusting such pharmacokinetic properties of the compounds as solubility and/or hydrophobicity, absorption in the gastrointestinal tract, bioavailability, tissue penetration, and rate of clearance.

Compounds of this invention may exist as acid addition salts, basic addition salts, or zwitterions. Salts of the compounds are prepared during their isolation or following their purification. Acid addition salts of the compounds are those derived from the reaction of the compounds with an acid. For example, the acetate, adipate, alginate,

bicarbonate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, formate, fumarate, glycerophosphate, glutamate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactobionate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, phosphate, picrate, propionate, succinate, tartrate, thiocyanate, trichloroacetic, trifluoroacetic, para-toluenesulfonate, and undecanoate, salts of the compounds and prodrugs thereof are embraced by this invention. When the compounds contain carboxylic acids, basic addition salts may be prepared therefrom by reaction with a base such as the hydroxide, carbonate, and bicarbonate of cations such as lithium, sodium, potassium, calcium, and magnesium.

Compounds of this invention may be administered with or without an excipient. Excipients include encapsulating materials or formulation additives such as absorption accelerators, antioxidants, binders, buffers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, perfumes, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, solubilizers, wetting agents, and mixtures thereof. Excipients for orally administered compounds in solid dosage forms include agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, ethanol, ethyl acetate, ethyl carbonate, ethyl cellulose, ethyl laureate, ethyl oleate, gelatin, germ oil, glucose, glycerol, groundnut oil, isopropanol, isotonic saline,

lactose, magnesium hydroxide, magnesium stearate, malt, olive oil, peanut oil, potassium phosphate salts, potato starch, propylene glycol, Ringer's solution, talc, tragacanth, water, safflower oil, sesame oil, sodium carboxymethyl cellulose, sodium lauryl sulfate, sodium phosphate salts, soybean oil, sucrose, tetrahydrofurfuryl alcohol, and mixtures. Excipients for ophthalmically and orally administered compounds in liquid dosage forms include benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, castor oil, corn oil, cottonseed oil, ethanol, ethyl acetate, ethyl carbonate, fatty acid esters of sorbitan, germ oil, groundnut oil, glycerol, isopropanol, olive oil, polyethylene glycols, propylene glycol, sesame oil, tetrahydrofurfuryl alcohol, water, and mixtures thereof. Excipients for osmotically administered compounds include chlorofluorohydrocarbons, ethanol, isopropanol, water, and mixtures thereof. Excipients for parenterally administered compounds include 1,3-butanediol, castor oil, corn oil, cottonseed oil, germ oil, groundnut oil, liposomes, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, U.S.P. or isotonic sodium chloride solution, water, and mixtures thereof. Excipients for rectally and vaginally administered compounds include cocoa butter, polyethylene glycol, wax, and mixtures thereof.

Compounds of this invention may be administered orally, ophthalmically, osmotically, parenterally (subcutaneously, intramuscularly, intrasternally, intravenously), rectally, topically, transdermally, and vaginally. Orally administered compounds in solid dosage forms may be administered as capsules, dragees, granules, pills, powders, and tablets. Ophthalmically and orally administered compounds in liquid dosage forms may be

administered as elixirs, emulsions, microemulsions, solutions, suspensions, and syrups. Osmotically and topically administered compounds may be administered as creams, gels, inhalants, lotions, ointments, pastes, powders, solutions, and sprays. Parenterally administered compounds may be administered as aqueous or oleaginous solutions or aqueous or oleaginous and suspensions, in which suspensions comprise crystalline, amorphous, or otherwise insoluble forms of the compounds. Rectally and vaginally administered compounds may be administered as creams, gels, lotions, ointments, and pastes.

Therapeutically effective amounts of compounds of this invention depend on the recipient of treatment, the disorder being treated and the severity of the disorder, the composition comprising the compounds, the time of administration, the route of administration, the duration of treatment, the potency of the compounds, and the rate of excretion of the compounds. The daily therapeutically effective amount of the compounds administered to a patient in single or divided doses range from about 0.1 to about 200 mg/kg body weight, preferably from about 0.25 to about 100 mg/kg body weight. Single dose compositions contain these amounts of the compounds or combinations of submultiples thereof.

To determine antibacterial activity of the compounds of this invention, twelve petri dishes, each containing successive aqueous dilutions of test compounds in sterilized Brain Heart Infusion agar (Difco 0418-01-5) (10 mL), were inoculated with 1:100 dilutions of the representative microorganisms in TABLE 1 using a Steers replicator block (or 1:10 dilutions for slow-growing Streptococcus strains), co-incubated at 35-37°C for 20-24 hours with a plate with a control plate having no compound, and inspected visually to

provide the minimum inhibitory concentration (MIC), in $\mu\text{g/mL}$, by which is meant the lowest concentration of the test compound which yielded no growth, a slight haze, or sparsely isolated colonies on the inoculums spot as compared to growth in the control plate.

TABLE 1

Microorganism	Code
Staphylococcus aureus NCTC10649M	AA
Staphylococcus aureus A5177	BB
Staphylococcus aureus PIU 2043	CC
Staphylococcus aureus 1775	DD
Streptococcus pyrogenes EES61	EE
Streptococcus pyrogenes 930	FF
Streptococcus pyrogenes PIU 2548	GG
Streptococcus pneumoniae ATCC 6303	HH
Streptococcus pneumoniae 5979	JJ
Streptococcus pneumoniae 5649	KK
Enterococcus faecalis PIU 1967	LL
Enterococcus faecium GYR 1632	MM
Moraxella catarrhalis 2604	NN
Haemophilus influenzae GYR 1435	PP
Escherichia coli JUHL	QQ

The ability of the compounds to inhibit bacterial growth was superior to the control and in the range of about 0.5 $\mu\text{g/mL}$ to greater than about 128 $\mu\text{g/mL}$ against the microorganisms listed in TABLE 1. These data demonstrate the usefulness of the compounds as antibacterials.

It is meant to be understood that certain metabolites of compounds of this invention, which metabolites are produced by in vitro or in vivo metabolic processes, would


also be useful as antibacterials and are meant to be embraced by this invention.

It is still also meant to be understood that certain precursor compounds, which precursor compounds may be
5 metabolized in vitro or in vivo to form compounds of this invention, are meant to be embraced by this invention.

Compounds of this invention may also be prepared by synthetic chemical processes, examples of which synthetic chemical processes, and intermediates employed in the
10 processes, are shown hereinbelow. It is meant to be understood that the order of the steps in the processes may be varied, reagents, solvents, and reaction conditions may be substituted for those specifically mentioned, and vulnerable moieties may be protected and deprotected, as
15 necessary, during the process.

Abbreviations used herein are DMF for N,N-dimethylformamide; THF for tetrahydrofuran.

SCHEME 1




The compound having formula (III) may be prepared from erythromycin A as described in U.S. 5,274,085, column 3,
 5 lines 41-48 and 5,808,017, column 4, lines 37-53.

The compound having formula (III) may be converted to the compound having formula (IV) as described in U.S. 4,990,602, column 23, lines 11-19.

The compound having formula (IV) may be converted to
 10 the compound having formula (V) as described in U.S. 4,990,602, column 23, lines 34-42.

The compound having formula (V) may be converted to compounds having formula (VI) by reacting the former, a compound having formula

15



in which X^2 is -Cl or -Br,
and a first base.

Examples of compounds having formula X^2-R^{11} include
compounds having formula X^2-R^{11} , $X^2-C(O)OR^{11}$, $X^2-C(O)NH_2$,
5 $X^2-C(O)NHR^{12}$, and $X^2-C(O)NR^{12}R^{13}$.

Examples of compounds having formula X^2-R^{11} include
bromomethane, 3-bromoprop-1-ene, 3-bromoprop-1-yne, benzyl
bromide, 2-fluoroethyl bromide, 4-nitrobenzyl bromide,
4-chlorobenzyl bromide, 4-methoxybenzyl bromide,
10 (3-bromoprop-1-enyl)benzene, 1-bromobut-2-ene,
2-(5-(3-bromoprop-1-ynyl)thien-2-yl)pyridine,
1-bromopent-2-ene, 2-(3-bromoprop-1-enyl)naphthalene,
5-(3-bromoprop-1-ynyl)-2-thien-2-ylpyridine,
2-(3-bromoprop-1-ynyl)pyridine,
15 3-((1E)-3-bromoprop-1-enyl)quinoline,
2-(5-(3-bromoprop-1-ynyl)isoxazol-3-yl)pyridine, and
2-(5-(3-bromoprop-1-ynyl)thien-2-yl)pyrimidine.

Examples of compounds having formula $X^2-C(O)OR^{11}$
include ethyl chloroformate, methyl chloroformate, phenyl
20 chloroformate, propargyl chloroformate, allyl chloroformate,
2-bromoethyl chloroformate, 1-chloroethyl chloroformate,
3-chloropropyl formate, 4-chlorobutyl formate, 3-butenyl
chloroformate, 2-methoxyphenyl chloroformate, para-toluene
chloroformate, and 4-methoxyphenyl chloroformate.

25 Examples of compounds having formula $X^2-C(O)NH_2$
are carbamic chloride and carbamic bromide.

Examples of compounds having formula $X^2-C(O)NHR^{12}$
include 4-chlorophenylcarbamic chloride,
5-bromo-1,1'-biphenyl-2-ylcarbamic chloride,
30 quinolin-8-ylcarbamic chloride, 2-methoxyphenylcarbamic
chloride, methylcarbamic chloride, cyclohexylcarbamic
chloride, 2-(dimethylamino)-4-methoxyphenylcarbamic

chloride, prop-2-ynylcarbamic chloride,
3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynylcarbamic chloride,
and 2,6-dimethylphenylcarbamic chloride.


Examples of compounds having formula $X^2-C(O)NR^{12}R^{13}$
5 include dimethylcarbamic chloride, diethylcarbamic chloride,
diisopropylcarbamic chloride, diallylcarbamic chloride,
4-ethoxyphenyl(pyridin-2-yl)carbamic chloride,
methyl(phenyl)carbamic chloride, methyl(vinyl)carbamic
chloride, diphenylcarbamic chloride,
10 ethyl(3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl)carbamic
chloride, and 2-chloroprop-2-enyl(propyl)carbamic chloride.

Examples of first bases include pyridine,
triethylamine, diisopropylethylamine,
4-(N,N-dimethylamino)pyridine, sodium hydroxide, potassium
15 hydroxide, potassium tert-butoxide, sodium carbonate, sodium
bicarbonate, cesium hydroxide, tetramethylammonium
hydroxide, sodium hydride, potassium hydride, potassium
isopropoxide, potassium isobutoxide, and mixtures thereof.

The reaction is typically conducted over about 0.5
20 hours to about 8 hours, at about -15°C to about 50°C, in
solvents such as tetrahydrofuran, diethylether, ethyl
acetate, acetone, N,N-dimethylformamide, dimethylsulfoxide,
diethylsulfoxide, 1,2-dimethoxyethane, dichloromethane,
chloroform, and mixtures thereof.

25

SCHEME 2



Compounds having formula (VI) may be converted to compounds having formula (VII) as described in U.S.

5 4,672,109, column 19-20, lines 54-64 and 1-2, respectively and U.S. 5,808,017, column 4, lines 21-29.

Compounds having formula (VII) may be converted to compounds having formula (VIII), in which R^P is acetyl ($\text{CH}_3\text{C}(\text{O})-$), or benzoyl ($\text{C}_6\text{H}_5\text{C}(\text{O})-$), by reacting the former, a hydroxyl protecting group precursor and a second base,

10 with or without 4-(N,N-dimethylamino)pyridine.


Examples of hydroxyl protecting group precursors include acetic anhydride and benzoic anhydride.

Examples of second bases include triethylamine,

15 diisopropylethylamine, and pyridine.


The reaction is typically conducted over about 1 hour to about 24 hours, at about 25°C to about 75°C, in solvents such as tetrahydrofuran, dimethylsulfoxide, acetonitrile, dichloromethane, chloroform, N,N-dimethylformamide, and mixtures thereof.

SCHEME 3



Compounds having formula (VIII) may be converted to compounds having formula (IX), in which R^{P1} is trialkylsilyl, by (a) protecting the 11,12-diol using the same reagents and under the same conditions as described in J.Org. Chem., Vol. 53, No. 10, 1988, p.2344, (b) removing the cladinoso moiety from the product obtained from step (a) using the same reagents and under the same conditions described for the conversion of the compounds having formula (I)-a to the compounds having formula (II)-a in SCHEME 9, (c) silylating the product obtained from step (b) using the same reagents and under the same conditions described for the conversion of the compounds having formula (IV) to the compounds having formula (V) in SCHEME 1, and (d) dehydrating the product from step (c) using the same reagents and under the same conditions described in J.Org. Chem., Vol. 53, No. 10, 1988, p.2344.

SCHEME 4



Compounds having formula (VIII) may be converted to compounds having formula (X) by (a) reacting the former and an activating agent, with or without the second base, and with or without 4-(N,N-dimethylamino)pyridine, and (b) reacting the product of step (a) and a third base.

Examples of activating agents include methanesulfonyl chloride, methanesulfonic anhydride, para-toluenesulfonyl chloride, and acetic anhydride.

Examples of third bases include sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, lithium diisopropylamide, lithium tetramethylpiperidide, tetramethylguanidine, 1,8-diazabicyclo(5.4.0)undec-7-ene, and mixtures thereof.

Step (a) is typically conducted over about 1 hour to about 24 hours, at about -10°C to about 40°C , in solvents such as pyridine, tetrahydrofuran, ether, dichloromethane,

chloroform, dimethylsulfoxide, N,N-dimethylformamide, acetonitrile, and mixtures thereof.

Step (b) is typically conducted over about 1 hour to about 3 days, at about -78°C to about 80°C, in solvents such as acetone, tetrahydrofuran, N,N-dimethylformamide, dioxane, 1,2-dimethoxyethane, acetonitrile, and mixtures thereof.

Compounds having formula (X) may be converted to compounds having formula (XI) by reacting the former, a compound having formula $(X^2CHR^{10}CO)_2O$, and the second base, with or without 4-(N,N-dimethylamino)pyridine.

Examples of compounds having formula $(X^2CHR^{10}CO)_2O$ include chloroacetic anhydride, 2-chloropropanoic anhydride, and 2-chlorobutanoic anhydride, bis(1-chlorobut-3-enyl) carbonate, and bis(1-chlorobut-3-ynyl) carbonate.

The reaction is typically conducted over about 1 hour to about 72 hours, at about -10°C to about 35°C, in solvents such as dichloromethane, tetrahydrofuran, acetonitrile, chloroform, N,N-dimethylformamide, 1,2-dimethoxyethane, and mixtures thereof.


Compounds having formula (XI) may be converted to compounds having formula (XII) by reacting the former and a compound having formula R^5NH_2 .

Examples of compounds having formula R^5NH_2 include allylamine, benzylamine, 2,4-dimethoxybenzylamine, ethylamine, 4-methoxybenzylamine, methylamine, propylamine, propargylamine, propylamine, 3-(5-pyridin-2-yl-thiophen-2-yl)allylamine, 3-(5-pyridin-2-yl-thiophen-2-yl)propargylamine, and (2E)-3-quinolin-3-ylprop-2-en-1-amine.

The reaction is typically conducted over about 1 hour to about 72 hours, at about -10°C to about 50°C, in the compound having R^5NH_2 itself or in solvents such as

N,N-dimethylformamide, pyridine, dichloromethane, chloroform, tetrahydrofuran, and mixtures thereof.

SCHEME 5




Compounds having formula (XII) may be converted to compounds having formula (I)-a by reacting the former, a compound having formula $R^6\text{CHO}$ or an acetal thereof, and a first acid.

Examples of compounds having formula $R^6\text{CHO}$ include acetaldehyde, acrolein, benzaldehyde, formaldehyde, 4-pentenaldehyde, and propionaldehyde.

Examples of first acids include hydrochloric acid, para-toluenesulfonic acid, acetic acid, formic acid, boron trifluoride, and aluminum chloride.


The reaction is typically conducted at about 25°C to about 150°C, over about 1 hour to about 10 days, in solvents such as toluene, benzene, xylene, and mixtures thereof.

SCHEME 6



Compounds having formula (IX), in which R^{P1} is trimethylsilyl or triethylsilyl, may be converted to compounds having formula (XIV) using the same reagents and under the same conditions described for the conversion of compounds having formula (X) to compounds having formula (XII) in SCHEME 4.

SCHEME 7



Compounds having formula (XIV) may be converted to compounds having formula (XV) using the same reagents and under the same conditions described for the conversion of compounds having formula (XII) to compounds having formula (I)-a in SCHEME 5.


Compounds having formula (XV) may be converted to compounds having formula (II)-a by reacting the former and a fluoride-donating agent.

Examples of fluoride-donating agents include tetrabutylammonium fluoride, tetrabutylammonium chloride/potassium fluoride monohydrate, HF·pyridine, hydrogen fluoride, and ammonium fluoride.

The reaction is typically conducted at about 25°C to about 100°C, over about 1 hour to about 48 hours, in

solvents such as benzene, toluene, tetrahydrofuran, water, acetone, and mixtures thereof.

SCHEME 8



5

Compounds having formula (I)-b may be converted to compounds having formula (I)-c using the same reagents and under the same conditions described for the conversion of compounds having formula (VII) to compounds having formula (VIII) in SCHEME 2 except using only one equivalent of the hydroxyl protecting group precursor.

Compounds having formula (I)-c may be converted to compounds having formula (I)-d by reacting the former and an oxidant, with or without the second base.

Examples of oxidants include triacetoxy periodinane, N-chlorosuccinimide·dimethyl sulfide, dicyclohexyl carbodiimide·dimethyl sulfoxide·pyridinium trifluoroacetate,


oxalyl chloride·dimethylsulfoxide, and sulfur trioxide·pyridine·dimethylsulfoxide.

The reaction is typically conducted at about -20°C to about 35°C, over about 1 hour to about 72 hours, in solvents such as water, dichloromethane, acetonitrile, chloroform, tetrahydrofuran, and mixtures thereof.

Compounds having formula (I)-d may be converted to compounds having formula (I)-e by reacting the former and a sulfur ylide.

Examples of sulfur ylides include dimethyloxosulfonium methylide and dimethylsulfonium methylide.

SCHEME 9




Compounds having formula (I)-a may be converted to compounds having formula (II)-a by reacting the former and a second acid.

Examples of second acids include hydrochloric acid, sulfuric acid, perchloric acid, chloroacetic acid, dichloroacetic acid, and trifluoroacetic acid.

The reaction is typically conducted at about -10°C to about 70°C, over about 1 hour to about 72 hours, in solvents such as dichloromethane, tetrahydrofuran, methanol, ethanol, isopropanol, butanol, and mixtures thereof.

Compounds having formula (II)-a may be converted to compounds having formula (II)-b, in which R^9 is other than -OH, by reacting the former and a compound having formula X^2-R^{32} using the same reagents and under the same conditions described for the conversion of compounds having formula (V) to compounds having formula (VI) in SCHEME 1.

SCHEME 10



Compounds having formula (II)-a may be converted to compounds having formula (II)-c using the same reagents and under the same conditions described for the conversion of compounds of formula (I)-c to compounds of formula (I)-d in SCHEME 8.

Compounds having formula (II)-c may be converted to compounds having formula (II)-d by reacting the former and a fluorinating agent, with or without a fourth base.

Examples of fluorinating agents used without the fourth base include 10% F₂ in formic acid, 3,5-dichloro-1-fluoropyridinium tetrafluoroborate, 3,5-dichloro-1-fluoropyridinium triflate, and N-tetrafluoro-N-((trifluoromethyl)sulfonyl)methanesulfonamide. Examples of fluorinating agents used with the fourth base include N-fluorobenzenesulfonimide, N-fluoro-N-methyl-para-toluenesulfonamide, N-fluoropyridinim

triflate,

1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo(2.2.2)octane
bis(tetrafluoroborate) (SELECTFLUORTM), and
N-fluoroperfluoropiperidine.

5 Examples of fourth bases include sodium hydride,
potassium hydride, trimethylamine, lithium
bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide,
and potassium bis(trimethylsilyl)amide.


Compounds having formula (I) or formula (II), in which
10 R^D is acetyl or benzoyl, may be converted to compounds
having formula (I) or formula (II), in which R² is hydrogen,
by reacting the former and a deprotecting agent.

Examples of deprotecting agents include acids such as methanol, ethanol, acetic acid, and formic acid and bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, potassium carbonate, and ammonia.

The reaction is typically conducted at about 25°C to about 70°C, over about 1 hour to about 72 hours, in solvents such as water, methanol, ethanol, and mixtures thereof.

20

SCHEME 11



Compounds having formula (I)-c may be converted to compounds having formula (I)-f by (a) reacting the former, a
25 third acid, a diazo compound, and a phosphine, and (b)

reacting the product of step (a) and an alkali metal hydroxide.

Examples of third acids include benzoic acid and 4-nitrobenzoic acid.

5 Examples of diazo compounds include diethyl azodicarboxylate and diisopropyl azodicarboxylate.


Examples of phosphines include triphenyl phosphine and tributyl phosphine.

10 Examples of alkali metal hydroxides include lithium hydroxide, sodium hydroxide, and potassium hydroxide.

Step (a) is typically conducted over about 1 hour to about 8 hours, at about 0°C to about 85°C, in solvents such as tetrahydrofuran, dichloromethane, chloroform, benzene, toluene, xylene, and mixtures thereof.

15 Step (b) is typically conducted over about 1 hour to about 24 hours, at about 25°C to about 55°C, in solvents such as methanol, ethanol, isopropanol, and mixtures thereof.

SCHEME 12



Compounds having formula (II), in which R⁵ is prop-2-enyl, may be converted to compounds having formula (II)-e by reacting the former, a palladium reagent, and a fourth acid.

The reaction is typically conducted at about 25°C to about 100°C, over about 2 hours to about 48 hours, in solvents such as toluene, tetrahydrofuran, dichloromethane, 1,2-dimethoxyethane, and mixtures thereof.

Examples of the palladium reagents include palladium on carbon, tetrakis palladium(0)(triphenylphosphine), and Pd(dibenzylideneacetone)diphenylphosphinobutane.

Examples of the fourth acids include methanesulfonic acid, thiobenzoic acid, and N,N-dimethylbarbituric acid.

Compounds having formula (II), in which R⁵ is 2,4-dimethoxybenzyl, may be converted to compounds having

formula (II)-e by reacting the former and trifluoroacetic acid.

The reaction is typically conducted at about 25°C to about 75°C, over about 2 hours to about 48 hours, in
5 solvents such as dichloromethane, chloroform, acetonitrile, tetrahydrofuran, and mixtures thereof.

Compounds having formula (II)-e may be converted to compounds having formula (II) by reacting the former and a compound having formula X^2-R^5 under the same conditions
10 described for the conversion of compounds of formula (V) to compounds of formula (VI) in SCHEME 1.

Examples of compounds having formula X^2-R^5 include compounds having formula X^2-R^{19} , $X^2-C(O)OR^{19}$, $X^2-C(O)NH_2$, $X^2-C(O)NHR^{20}$, and $X^2-C(O)NR^{20}R^{21}$.

15 Examples of compounds having formula X^2-R^{19} include bromomethane, 3-bromoprop-1-ene, 3-bromoprop-1-yne, benzyl bromide, 2-fluoroethyl bromide, 4-nitrobenzyl bromide, 4-chlorobenzyl bromide, 4-methoxybenzyl bromide, (3-bromoprop-1-enyl)benzene, 1-bromobut-2-ene,
20 2-(5-(3-bromoprop-1-ynyl)thien-2-yl)pyridine, 1-bromopent-2-ene, 2-(3-bromoprop-1-enyl)naphthalene, 5-(3-bromoprop-1-ynyl)-2-thien-2-ylpyridine, 2-(3-bromoprop-1-ynyl)pyridine, 3-((1E)-3-bromoprop-1-enyl)quinoline,
25 2-(5-(3-bromoprop-1-ynyl)isoxazol-3-yl)pyridine, and 2-(5-(3-bromoprop-1-ynyl)thien-2-yl)pyrimidine.

Examples of compounds having formula $X^2-C(O)OR^{19}$ include ethyl chloroformate, methyl chloroformate, phenyl chloroformate, propargyl chloroformate, allyl chloroformate,
30 2-bromoethyl chloroformate, 1-chloroethyl chloroformate, 3-chloropropyl formate, 4-chlorobutyl formate, 3-butenyl

chloroformate, 2-methoxyphenyl chloroformate, para-toluene chloroformate, and 4-methoxyphenyl chloroformate.

Examples of compounds having formula $X^2-C(O)NH_2$ are carbamic chloride and carbamic bromide.

5 Examples of compounds having formula $X^2-C(O)NHR^{20}$ include 4-chlorophenylcarbamic chloride, 5-bromo-1,1'-biphenyl-2-ylcarbamic chloride, quinolin-8-ylcarbamic chloride, 2-methoxyphenylcarbamic chloride, methylcarbamic chloride, cyclohexylcarbamic
10 chloride, 2-(dimethylamino)-4-methoxyphenylcarbamic chloride, prop-2-ynylcarbamic chloride, 3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynylcarbamic chloride, and 2,6-dimethylphenylcarbamic chloride.

 Examples of compounds having formula $X^2-C(O)NR^{20}R^{21}$
15 include dimethylcarbamic chloride, diethylcarbamic chloride, diisopropylcarbamic chloride, diallylcarbamic chloride, 4-ethoxyphenyl(pyridin-2-yl)carbamic chloride, methyl(phenyl)carbamic chloride, methyl(vinyl)carbamic chloride, diphenylcarbamic chloride,
20 ethyl(3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl)carbamic chloride, and 2-chloroprop-2-enyl(propyl)carbamic chloride.

 Compounds having formula (II)-e may also be converted to compounds having formula (II), in which R^5 is $-R^{19}$, by reacting the former, a compound having formula R^5CHO or the
25 corresponding acetal, and a reducing agent, with or without the first acid.

 Examples of reducing agents include sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, zinc/hydrochloric acid, iron pentacarbonyl/alcoholic
30 potassium hydroxide, borane·pyridine, and formic acid.

Examples of compounds having formula R^5CHO include formaldehyde, acrolein, 4-pentenaldehyde, acetaldehyde, propionaldehyde, and benzaldehyde.

The reaction is typically conducted at about $-10^{\circ}C$ to
5 about $150^{\circ}C$, over about 1 hour to about 10 days, in solvents such as tetrahydrofuran, dichloromethane, toluene, benzene, xylene, N,N-dimethylformamide, and mixtures thereof.

The following examples illustrate methods by which
certain preferred first embodiments of the invention may be
10 prepared.

EXAMPLE 1

compound having formula (VIII): R^1 is $-CH_2C\equiv C-H$; R^P is
 $-C(O)$ (phenyl)

15 This example was prepared from erythromycin A (obtained from Abbott Laboratories) as described in SCHEME 1 and SCHEME 2. ^{13}C NMR ($CDCl_3$) δ 219.9, 174.9, 166.1, 165.4, 133.4, 132.6, 130.8, 129.8, 129.6, 128.4, 128.2, 99.9, 95.9, 81.1, 80.4, 80.1, 78.8, 78.2, 76.6, 74.4, 73.8, 72.9, 72.6,
20 68.7, 67.5, 63.6, 51.6, 49.6, 45.2, 44.6, 40.9, 38.0, 37.8, 37.4, 35.4, 31.6, 26.9, 21.3, 21.1, 20.2, 18.5, 18.2, 16.2, 16.1, 12.3, 10.5, 9.5.

EXAMPLE 2

25 compound having formula (X): R^1 is $-CH_2C\equiv C-H$, R^P is
 $-C(O)$ (phenyl)

A solution of EXAMPLE 1 (2.605g) in pyridine (13 mL) at $10^{\circ}C$ was treated with methansulfonic anhydride (1.2 g), stirred at $25^{\circ}C$ for 20 hours, and concentrated. The
30 concentrate was dissolved in dichloromethane (50 mL), washed with saturated aqueous $NaHCO_3$, and dried (Na_2SO_4), filtered, and concentrated. A solution of the concentrate and

1,8-diazabicyclo(5.4.0)undec-7-ene (0.60 mL) in acetone (15 mL) was stirred for 20 hours and concentrated; and the concentrate was flash chromatographed on silica gel with 15-40% acetone/hexane. ^1H NMR (CDCl_3) δ 8.06-7.98 (m, 4H),
5 7.63-7.38 (m, 6H), 6.48 (s, 1H), 5.05 (dd, $J=10.5$, 7.4Hz, 1H), 4.97-4.87 (m, 3H), 4.82 (d, $J=7.2\text{Hz}$, 1H), 4.51 (m, 1H), 4.23 (m, 2H), 3.94 (d, $J=7.8\text{Hz}$, 1H), 3.82 (m, 1H), 3.63 (d, $J=6.6\text{Hz}$, 1H), 3.48 (s, 3H), 3.34 (m, 1H), 2.93 (m, 1H), 2.75 (m, 1H), 2.58 (d, $J=15.3\text{Hz}$, 1H), 2.36 (t, $J=2.1\text{Hz}$, 1H), 2.31
10 (s, 6H), 2.00 (d, $J=0.9\text{Hz}$, 2H), 1.91-1.70 (m, 6H), 1.54 (s, 3H), 1.51 (m, 2H), 1.43 (m, 4H), 1.28-1.16 (m, 13H), 1.00 (d, $J=6\text{Hz}$, 3H), 0.86 (t, $J=7.2\text{Hz}$, 3H), 0.75 (d, $J=7.5\text{Hz}$, 3H).

15

EXAMPLE 3A

compound having formula (XI): R^1 is $-\text{CH}_2\text{C}\equiv\text{C}-\text{H}$, R^{10} is hydrogen, R^P is $-\text{C}(\text{O})(\text{phenyl})$

A solution of EXAMPLE 2 (2.19g), triethylamine (300 μL), and 4-(N,N-dimethylamino)pyridine (20 mg) in
20 dichloromethane (50 mL) at 0°C was treated with chloroacetic anhydride (840 mg), stirred at 25°C for 30 minutes, washed with saturated aqueous NaHCO_3 , and dried (Na_2SO_4), filtered, and concentrated; and the concentrate was flash chromatographed on silica gel with 15-50% acetone/hexane.
25 ^1H NMR (CDCl_3) δ 8.07-7.98 (m, 4H), 7.63-7.38 (m, 6H), 6.60 (s, 1H), 5.75 (dd, $J=10.2$, 3.3Hz, 1H), 5.03 (m, 2H), 4.94 (d, $J=9.9\text{Hz}$, 1H), 4.82 (d, $J=7.8\text{Hz}$, 1H), 4.51 (m, 1H), 4.22 (m, 2H), 3.96 (s, 2H), 3.81 (m, 2H), 3.62 (d, $J=6.6\text{Hz}$, 1H), 3.46 (s, 3H), 3.41 (m, 1H), 2.91 (m, 1H), 2.79 (m, 1H), 2.45
30 (d, $J=14.7\text{Hz}$, 1H), 2.38 (t, $J=2.1\text{Hz}$, 1H), 2.30 (s, 6H), 1.83 (s, 2H), 1.75 (m, 4H), 1.54 (s, 3H), 1.50 (m, 4H), 1.36 (s,

3H), 1.24 (m, 11H), 1.15 (d, J=6.3Hz, 3H), 1.00 (m, 2H),
0.84 (t, J=7.5Hz, 3H), 0.75 (d, J=7.5Hz, 3H).

EXAMPLE 3B

5 compound having formula (XII): R¹ is -CH₂C≡C-H, R⁵ is
methyl, R¹⁰ is hydrogen, R^P is -C(O)(phenyl)

A solution of EXAMPLE 3A (2.38 g) and 2M methylamine in
THF (3.5 mL) in DMF (20 mL) at 25°C was stirred for 18
hours, treated with more 2M methylamine in tetrahydrofuran
10 (3 mL), stirred for 48 hours, and concentrated; and the
concentrate was flash chromatographed on silica gel with
0.25% concentrated ammonium hydroxide/(95:5 dichloromethane/
methanol). ¹³C NMR (CDCl₃) δ 205.8, 174.0, 169.8, 166.2,
165.2, 140.2, 137.2, 133.4, 132.5, 130.7, 129.8, 129.7,
15 128.4, 128.1, 100.5, 96.5, 81.9, 81.0, 80.4, 79.7, 79.1,
78.9, 76.6, 75.6, 73.4, 72.9, 72.3, 67.9, 63.6, 63.5, 51.9,
51.8, 49.7, 45.1, 40.8, 39.6, 39.1, 36.0, 35.6, 32.0, 23.6,
21.7, 21.25, 21.2, 19.0, 18.5, 17.2, 16.1, 13.0, 10.1.

20

EXAMPLE 3C

compound having formula (I)-a: R¹ is -CH₂C≡C-H, R⁵ is
methyl, R¹⁰ is hydrogen, R^P is -C(O)(phenyl)

A solution of EXAMPLE 3B (1.57g), 37% aqueous
formaldehyde (115 µL), and acetic acid (2 drops) in toluene
25 (40 mL) was stirred for 30 minutes at 25°C and at 110°C for
1.5 hours under a Dean-Stark trap, and concentrated; and the
concentrate was flash chromatographed on silica gel with
10-25% acetone/hexane. ¹³C NMR (CDCl₃) δ 217.4, 178.1,
176.8, 166.2, 165.3, 133.3, 132.6, 130.7, 129.9, 129.8,
30 129.6, 128.4, 128.2, 100.8, 95.4, 86.4, 83.0, 80.7, 79.6,
79.0, 78.5, 76.5, 74.9, 70.3, 72.2, 67.8, 67.2, 66.2, 63.7,
63.4, 56.5, 53.0, 52.0, 49.7, 45.1, 42.0, 41.3, 40.9, 39.9,

37.8, 35.0, 32.2, 23.9, 23.6, 21.5, 21.3, 21.2, 19.6, 18.4,
16.2, 15.2, 10.5, 9.5.

EXAMPLE 3D

5 (2aR,4aS,6R,8S,9R,10S,11S,12R,15R,15aS,15bS)-15-ethyl-
3,4a,6,8,10,12,15a-heptamethyl-2,5,13-trioxo-8-(prop-2-
ynyloxy)-9-((3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl)oxy)hexadecahydro-2H-1,14-dioxo-3-
azacyclotetradeca(1,2,3-cd)pentalen-11-yl 4-O-benzoyl-2,6-
10 dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

A solution of EXAMPLE 3C (60 mg) in methanol (10 mL)
was refluxed for 24 hours and concentrated; and the
concentrate was flash chromatographed on silica gel with
84:15:1 dichloromethane/methanol/concentrated ammonium
15 hydroxide. ^{13}C NMR (CDCl_3) δ 217.0, 178.2, 176.9, 166.1,
133.3, 130.0, 129.6, 128.3, 102.8, 95.4, 86.5, 83.0, 80.7,
79.6, 79.1, 78.8, 76.7, 75.0, 72.8, 71.0, 68.1, 67.2, 66.2,
65.4, 63.4, 56.6, 53.0, 52.1, 49.6, 45.3, 42.0, 41.4, 40.5,
40.4, 37.7, 34.9, 29.3, 23.9, 23.6, 21.5, 21.4, 21.2, 19.7,
20 18.3, 16.3, 15.1, 10.5, 9.3.

EXAMPLE 3E

A solution of EXAMPLE 3C (815 mg) in dichloromethane
(20 mL) and trifluoroacetic acid (1 mL) at 25°C was stirred
25 for one hour, treated with more trifluoroacetic acid (1 mL),
stirred for another hour, washed with saturated aqueous
 NaHCO_3 , and dried (Na_2SO_4), filtered, and concentrated; and
the concentrate was flash chromatographed on silica gel with
10-40% acetone/hexane. ^1H NMR (CDCl_3) δ 8.05 (m, 2H), 7.55
30 (m, 1H), 7.43 (m, 2H), 5.05 (dd, $J=10.5$, 7.8Hz, 1H), 4.75
(d, $J=7.8$ Hz, 1H), 4.59 (dd, $J=10.5$, 2.1Hz, 1H), 4.00 (m,
2H), 3.71 (d, $J=2.7$ Hz, 1H), 3.61-3.45 (m, 4H), 2.91 (m, 3H),

2.70 (m, 2H), 2.66 (s, 3H), 2.40 (t, J=2.4Hz, 1H), 2.32 (m, 1H), 2.28 (s, 6H), 1.77 (m, 2H), 1.67 (s, 3H), 1.60 (m, 2H), 1.54 (s, 3H), 1.51 (m, 2H), 1.44 (d, J=3.3Hz, 3H), 1.28 (d, J=6.0Hz, 3H), 1.16 (d, 3H, J=6.9Hz), 0.92 (d, J=6.9Hz, 3H),
5 0.81 (d, J=7.2Hz 3H), 0.79 (t, J=7.5Hz, 3H).

EXAMPLE 3F

A solution of EXAMPLE 3E (612 mg) and triacetoxyp
periodinane (430 mg) in dichloromethane (10 mL) at 25°C was
10 stirred for 1 hour, diluted with dichloromethane, washed
sequentially with saturated aqueous NaHCO₃, saturated
aqueous sodium thiosulfate, and brine, and dried (Na₂SO₄),
filtered, and concentrated. ¹H NMR (CDCl₃) δ 8.02 (m, 2H),
7.56 (m, 1H), 7.44 (m, 2H), 5.03 (dd, J=10.5, 7.5Hz, 1H),
15 4.57 (dd, J=9.9, 2.4Hz, 1H), 4.51 (d, J=7.5Hz, 1H), 4.20
(d, J=7.5Hz, 1H), 3.76 (q, J=7.2Hz, 1H), 3.70 (t, J=2.1Hz,
2H), 3.62 (m, 1H), 3.53 (d, J=8.1Hz, 1H), 3.45 (d, J=10.5Hz,
1H), 3.04-2.80 (m, 4H), 2.68 (d, J=10.5Hz, 1H), 2.64 (s,
3H), 2.36 (t, J=2.1Hz, 1H), 2.27 (s, 6H), 2.17 (dd, J=15,
20 9Hz, 1H), 1.80 (m, 2H), 1.70 (s, 3H), 1.60 (m, 3H), 1.49 (s,
3H), 1.47 (s, 3H), 1.33 (d, 3H, J=7.2Hz), 1.30 (d, J=5.7Hz,
3H), 1.00 (d, J=3.3Hz, 3H), 0.98 (d, J=3.3Hz, 3H), 0.80 (t,
J=7.2Hz, 3H).

25

EXAMPLE 3G

30

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-
3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-(prop-2-
ynyloxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca-
(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)-β-
D-xylo-hexopyranoside

A solution of EXAMPLE 3F (60 mg) in methanol (5 mL) was
heated at 60°C for 36 hours and concentrated; and the

concentrate was flash chromatographed on silica gel with 84:15:1 of dichloromethane/methanol/concentrated ammonium hydroxide. ^{13}C NMR (CDCl_3) δ 216.9, 205.8, 176.5, 170.4, 104.0, 85.7, 83.9, 80.4, 80.2, 78.8, 77.4, 74.4, 70.4, 69.5, 67.5, 66.1, 65.8, 56.6, 52.7, 51.4, 50.7, 48.5, 41.9, 40.3, 39.2, 36.6, 28.5, 22.3, 21.8, 21.2, 19.6, 16.9, 15.8, 14.3, 10.4.

EXAMPLE 4A

A solution of EXAMPLE 3F (520 mg), triethylamine (5 mL), 2-(5-bromothien-2-yl)pyridine (250 mg), tris(dibenzylideneacetone)dipalladium(0) (55 mg), bis(1,2-diphenylphosphino)ethane (48 mg), and copper(I) iodide (4 mg) in acetonitrile (10 mL) at 80°C was stirred for 3 hours, cooled to room temperature, and concentrated; and the concentrate was flash chromatographed on silica gel with 10-40% acetone/hexane. ^1H NMR (CDCl_3) δ 8.56 (m, 1H), 8.03 (m, 2H), 7.73-7.54 (m, 3H), 7.47-7.41 (m, 3H), 7.17 (m, 1H), 7.13 (d, $J=4.2\text{Hz}$, 1H), 5.05 (dd, $J=10.5$, 7.2Hz , 1H), 4.59 (dd, $J=10.5$, 2.7Hz , 1H), 4.53 (d, $J=7.8\text{Hz}$, 1H), 4.29 (d, $J=8.1\text{Hz}$, 1H), 3.95 (s, 2H), 3.80 (q, $J=6.9\text{Hz}$, 1H), 3.62 (m, 1H), 3.48 (d, $J=8.1\text{Hz}$, 1H), 3.41 (d, $J=10.2\text{Hz}$, 1H), 3.06 (quintet, $J=7.5\text{Hz}$, 1H), 2.91 (d, $J=8.1\text{Hz}$, 1H), 2.95-2.80 (m, 2H), 2.67 (d, $J=10.5\text{Hz}$, 1H), 2.52 (s, 3H), 2.28 (s, 6H), 2.23 (m, 1H), 1.80 (m, 2H), 1.72 (s, 3H), 1.60 (m, 1H), 1.54 (s, 3H), 1.50 (m, 2H), 1.48 (s, 3H), 1.35 (d, $J=6.9\text{Hz}$, 3H), 1.31 (d, $J=5.7\text{Hz}$, 3H), 1.02 (d, $J=2.7\text{Hz}$, 3H), 1.00 (d, $J=3.3\text{Hz}$, 3H), 0.81 (t, $J=7.5\text{Hz}$, 3H).

EXAMPLE 4B

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy)hexadecahydro-2H-

1,14-dioxa-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside

A solution of EXAMPLE 4A (445 mg) in methanol (20 mL) was refluxed for 20 hours and concentrated; and the

5 concentrate was flash chromatographed on silica gel with 90:10:0.5 dichloromethane/methanol/concentrated ammonium

hydroxide. ^{13}C NMR (CDCl_3) δ 217.1, 205.9, 176.6, 170.6,

151.7, 149.7, 146.0, 136.7, 132.6, 124.5, 124.1, 122.4,

118.7, 104.1, 94.4, 85.8, 80.3, 80.2, 79.7, 78.5, 70.4,

10 69.6, 67.4, 66.1, 65.8, 56.6, 52.7, 52.4, 50.6, 48.6, 42.2,

40.3, 39.6, 37.0, 28.4, 22.7, 22.5, 21.7, 21.3, 19.7, 16.9,

15.9, 14.3, 10.4.

EXAMPLE 5

15 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-ethyl-8-methoxy-4a,6,8,10,12,15a-hexamethyl-2,5,13-trioxo-9-((3,4,6-

trideoxy-3-(dimethylamino)- β -D-xylo-

hexopyranosyl)oxy)hexadecahydro-2H-1,14-dioxa-3-

azacyclotetradeca(1,2,3-cd)pentalen-11-yl 2,6-dideoxy-3-C-

20 methyl-3-O-methyl- α -L-ribo-hexopyranoside;

This example was prepared as described in SCHEME 3.

EXAMPLE 6A

A solution of EXAMPLE 5 (1.13 g), triethylamine (0.5
25 mL), and 4-(N,N-dimethylamino)pyridine (10 mg) in

dichloromethane (80 mL) at 0°C was treated with chloroacetic anhydride (1.18 g), stirred at 25°C for 3 hours, washed with

saturated aqueous NaHCO_3 , and dried (Na_2SO_4), filtered, and

concentrated; and the concentrate was flash chromatographed

30 on silica gel with 30% acetone/hexane.

EXAMPLE 6B

A solution of EXAMPLE 6A (4.08g) and allylamine (2.5 mL) at 25°C was stirred for 20 hours and concentrated; and the concentrate was flash chromatographed on silica gel with 89:10:1 dichloromethane/methanol/concentrated ammonium hydroxide.

EXAMPLE 6C

A solution of EXAMPLE 6B (2.77 g), 37% aqueous formaldehyde (160 µL) and acetic acid (10 drops) in toluene (80 mL) was stirred for 30 minutes at 25°C and at 110°C for 1.5 hours under a Dean-Stark trap, and concentrated; and the concentrate was flash chromatographed on silica gel with 10-50% acetone/hexane.

A solution of the product from the preceeding paragraph (2.48 g) in THF (50 mL) at 25°C was treated with 1M tetrabutylammonium fluoride in THF (3.3 mL), stirred for 2 hours, and concentrated. The concentrate was dissolved in dichloromethane (60 mL), treated with triacetoxy periodinane (3.56 g), stirred at 25°C for 2 hours, diluted with dichloromethane, washed sequentially with saturated aqueous NaHCO₃, saturated aqueous sodium thiosulfate, and brine, and dried (Na₂SO₄), filtered and concentrated; and the concentrate was flash chromatographed on silica gel with 1:1 of acetone/hexane.

EXAMPLE 6D

A solution of EXAMPLE 6C (100mg), tetrakis palladium(0) (triphenylphosphine) (16 mg), and N,N-dimethylbarbituric acid (65 mg) in dichloromethane (1 mL) at 35°C was stirred for 5 hours, treated with dichloromethane (70 mL), washed with saturated aqueous NaHCO₃ and brine, and dried (Na₂SO₄), filtered and concentrated; and the concentrate was flash

chromatographed on silica gel with 29.5:70:0.5%
acetone/hexane/ triethylamine.

EXAMPLE 6E

5 (2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-8-methoxy-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 11, 13-tetraoxohexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)-pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylohexopyranoside

10 A solution of EXAMPLE 6D in methanol (1 mL) at 25°C was stirred for 24 hours and concentrated; and the concentrate was flash chromatographed on silica gel with 94.5:5:0.5 dichloromethane/methanol/concentrated ammonium hydroxide.
 ^{13}C NMR (CDCl_3) δ 217.2, 205.5, 177.0, 170.3, 104.0, 86.4,
15 79.3, 78.5, 78.1, 70.4, 69.5, 65.7, 60.3, 59.2, 56.6, 52.6, 51.1, 50.6, 48.6, 40.8, 40.2, 36.7, 28.4, 21.6, 21.4, 21.2, 21.0, 19.8, 16.9, 16.1, 14.4, 10.3.

EXAMPLE 7A

20 A solution of EXAMPLE 6A (480 mg) and 2M methylamine in THF (1.5 mL) in N,N-dimethylformamide (3 mL) was stirred at 25°C for 6 hours and concentrated.

EXAMPLE 7B

25 A solution of EXAMPLE 7A (76 mg), 37% aqueous formaldehyde (7.2 μL), and acetic acid (one drop) in toluene (20 mL) was stirred for 30 minutes at 25°C and at 110°C for 1.5 hours under a Dean-Stark trap, and concentrated; and the concentrate was flash chromatographed on silica gel with 10-
30 50% acetone/hexane.

EXAMPLE 7C

A solution of EXAMPLE 7B (283 mg) in THF (5 mL) at 25°C was treated with 1M tetrabutylammonium fluoride in THF (0.4 mL), stirred for 1.5 hours, and concentrated. A solution of the concentrate (260 mg) in dichloromethane (8 mL) at 25°C
5 was treated with triacetoxy periodinane (190 mg), stirred for 1 hour, diluted with dichloromethane, washed with saturated aqueous NaHCO₃, saturated aqueous sodium thiosulfate, and brine, and dried (Na₂SO₄), filtered and concentrated; and the concentrate was flash chromatographed
10 on silica gel with 1:1 acetone/hexane.

EXAMPLE 7D


(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-8-methoxy-
3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 11, 13-
15 tetraoxohexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca-
(1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)-β-
D-xylo-hexopyranoside

A solution of EXAMPLE 7C (225 mg) in methanol (5 mL) at 55°C was stirred for 3 hours and concentrated; and the
20 concentrate was flash chromatographed on silica gel with 89/10/1 dichloromethane/methanol/concentrated ammonium hydroxide.

The foregoing is merely illustrative of the invention and is not intended to limit the same. Variations and
25 changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention as defined in the claims.


WHAT IS CLAIMED IS:

1. A compound having formula (I)



(I),

or formula (II),



(II),

or a salt, prodrug, or salt of a prodrug thereof, in which

R^1 is hydrogen, $-R^{11}$, $-C(O)OR^{11}$, $-C(O)NH_2$, $-C(O)NHR^{12}$,
 $-C(O)NR^{12}R^{13}$, $-CH_2R^{14}$, $-C(O)OCH_2R^{14}$, $-C(O)NHCH_2R^{14}$, or
 10 $-C(O)N(CH_2R^{14})_2$;

R^2 is hydrogen or R^P , in which R^P is a hydroxyl
 protecting moiety;

one of R^3 or R^4 is hydrogen and the other is $-OH$, $-OR^P$,
 $-OR^{15}$, $-OC(O)R^{15}$, $-OC(O)OR^{15}$, $-OC(O)NH_2$, $-OC(O)NHR^{16}$,
 15 $-OC(O)NR^{16}R^{17}$, $-OCH_2R^{18}$, or $-OC(O)OCH_2R^{18}$; or

R^3 and R^4 together are $=O$ or $-CH_2O-$;

R^5 is hydrogen, $-R^{19}$, $-C(O)OR^{19}$, $-C(O)NH_2$, $-C(O)NHR^{20}$,
 $-C(O)NR^{20}R^{21}$, $-CH_2R^{22}$, $-C(O)OCH_2R^{22}$, $-C(O)NHCH_2R^{22}$, or
 $-OC(O)N(CH_2R^{22})_2$;

20 R^6 and R^{10} are independently hydrogen or $-R^{23}$;

R^7 is $=O$, $=NOH$, $=NOR^P$, $=NOR^{24}$, or $=NO(CH_2)R^{25}$;

one of R^8 and R^9 is hydrogen, and the other is $-OH$ or
 $-OR^{32}$; or

R^8 and R^9 together are $=O$;

25 R^{11} , R^{15} , R^{19} , R^{24} , and R^{26} are independently alkyl,
 $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, alkyl substituted with one or
 two or three substituents independently selected from the
 group consisting of cycloalkyl, halo, aryl, heteroaryl, and
 heterocyclyl, $-(CH_2)alkenyl$ substituted with one or two or
 30 three substituents independently selected from the group
 consisting of cycloalkyl, halo, aryl, heteroaryl, and
 heterocyclyl, or $-(CH_2)alkynyl$ substituted with one or two
 or three substituents independently selected from the group
 consisting of cycloalkyl, aryl, heteroaryl, and
 35 heterocyclyl;

R^{12} , R^{13} , R^{16} , R^{17} , R^{20} , R^{21} , R^{27} , and R^{28} are
 independently alkyl, cycloalkyl, $-(CH_2)alkenyl$,

-(CH₂)alkynyl, aryl, heteroaryl, heterocyclyl, alkyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, 40 -NH₂, -NHR³⁰, and -NR³⁰R³¹, -(CH₂)alkenyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, -NH₂, -NHR³⁰, and -NR³⁰R³¹, or -(CH₂)alkynyl substituted with one 45 substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, -NH₂, -NHR³⁰, and -NR³⁰R³¹; or

R¹² and R¹³ together, R¹⁶ and R¹⁷ together, R²⁰ and R²¹ together, or R²⁷ and R²⁸ together are independently 50 C₃-C₆-alkylene, C₅-C₆-alkylene interrupted with one moiety selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, C₃-C₆-alkylene substituted with one substituent selected from the group consisting of -OH, -O(alkyl), =O, -NH₂, -NHR³⁰, and -NR³⁰R³¹, 55 or C₅-C₆-alkylene interrupted with one moiety selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one substituent selected from the group consisting of -OH, -O(alkyl), =O, -NH₂, -NHR³⁰, and -NR³⁰R³¹;

60 R¹⁴, R¹⁸, R²², R²⁵, and R²⁹ are independently alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- or alkyl interrupted with one or two or three moieties independently selected 65 from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group

consisting of cycloalkyl, halo, aryl, heteroaryl,
heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹;

70 R²³ is alkyl, alkenyl, alkynyl, aryl, heteroaryl,
heterocyclyl, alkyl substituted with one or two or three
substituents independently selected from the group
consisting of cycloalkyl, halo, aryl, heteroaryl, and
heterocyclyl, alkenyl substituted with one or two or three
75 substituents independently selected from the group
consisting of cycloalkyl, halo, aryl, heteroaryl, and
heterocyclyl, alkynyl substituted with one or two or three
substituents independently selected from the group
consisting of cycloalkyl, aryl, heteroaryl, and
80 heterocyclyl, alkyl interrupted with one or two or three
moieties independently selected from the group consisting
of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkyl
interrupted with one or two or three moieties independently
selected from the group consisting of -O-, -NH-,
85 -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one
or two or three substituents independently selected from
the group consisting of cycloalkyl, halo, aryl, heteroaryl,
heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹,
alkenyl interrupted with one or two moieties independently
90 selected from the group consisting of -O-, -NH-,
-N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkenyl interrupted
with one or two moieties independently selected from the
group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and
-SO₂- and substituted with one or two or three substituents
95 independently selected from the group consisting of
cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O,
-O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹, alkynyl interrupted
with one or two moieties independently selected from the
group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and

100 -SO₂-, or alkynyl interrupted with one or two moieties
independently selected from the group consisting of -O-,
-NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted
with one or two or three substituents independently
selected from the group consisting of cycloalkyl, halo,
105 aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂,
-NHR³⁰, and -NR³⁰R³¹;

R³⁰ and R³¹ are independently alkyl, cycloalkyl, aryl,
heteroaryl, heterocyclyl, -(CH₂)alkenyl, -(CH₂)alkynyl,
cycloalkyl, alkyl substituted with one substituent selected
110 from the group consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂,
-(CH₂)alkenyl substituted with one substituent selected
from the group consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂, or
115 -(CH₂)alkynyl substituted with one substituent selected
from the group consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂; or

R³⁰ and R³¹ together are C₃-C₆-alkylene, C₅-C₆-alkylene
interrupted with one moiety selected from the group
120 consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and
-SO₂-, C₃-C₆-alkylene substituted with one substituent
selected from the group consisting of -OH, -O(alkyl), =O,
-NH₂, -NH(alkyl), and -N(alkyl)₂, or C₅-C₆-alkylene
interrupted with one moiety selected from the group
125 consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-
and substituted with one substituent selected from the
group consisting of -OH, -O(alkyl), =O, -NH₂, -NH(alkyl),
and -N(alkyl)₂;

R^{32} is $-R^{26}$, $-C(O)OR^{26}$, $-C(O)NH_2$, $-C(O)NHR^{27}$,
130 $-C(O)NR^{27}R^{28}$, $-CH_2R^{29}$, $-C(O)OCH_2R^{29}$, $-C(O)NHCH_2R^{29}$, or
 $-C(O)N(CH_2R^{29})_2$; and

X^1 is hydrogen or fluoride.

2. The compound of claim 1 having formula (I) or formula (II), or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, in which

R^1 is hydrogen, $-R^{11}$, $-C(O)OR^{11}$, $-C(O)NH_2$, $-C(O)NHR^{12}$, or
5 $-C(O)NR^{12}R^{13}$;

R^2 is hydrogen or R^P , in which R^P is a hydroxyl protecting moiety;

one of R^3 or R^4 is hydrogen and the other is $-OH$, $-OR^P$,
 $-OR^{15}$, $-OC(O)R^{15}$, $-OC(O)OR^{15}$, $-OC(O)NH_2$, $-OC(O)NHR^{16}$, or
10 $-OC(O)NR^{16}R^{17}$; or

R^3 and R^4 together are $=O$ or $-CH_2O-$;

R^5 is hydrogen, $-R^{19}$, $-C(O)OR^{19}$, $-C(O)NH_2$, $-C(O)NHR^{20}$,
or $-C(O)NR^{20}R^{21}$;

R^6 and R^{10} are independently hydrogen or $-R^{23}$;

15 R^7 is $=O$, $=NOH$, $=NOR^P$, or $=NOR^{24}$;

one of R^8 and R^9 is hydrogen, and the other is $-OH$ or
 $-OR^{32}$; or

R^8 and R^9 together are $=O$;

R^{11} , R^{15} , R^{19} , R^{24} , and R^{26} are independently alkyl,
20 $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, alkyl substituted with one or
two or three substituents independently selected from the
group consisting of cycloalkyl, halo, aryl, heteroaryl, and
heterocyclyl, $-(CH_2)alkenyl$ substituted with one or two or
three substituents independently selected from the group
25 consisting of cycloalkyl, halo, aryl, heteroaryl, and

heterocyclyl, or $-(CH_2)alkynyl$ substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, aryl, heteroaryl, and heterocyclyl;

30 R^{12} , R^{13} , R^{16} , R^{17} , R^{20} , R^{21} , R^{27} , and R^{28} are independently alkyl, cycloalkyl, $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, 35 $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, $-(CH_2)alkenyl$ substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, or $-(CH_2)alkynyl$ substituted with one substituent selected from the group consisting of 40 cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$;

R^{23} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, alkyl substituted with one or two or three substituents independently selected from the group 45 consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, alkenyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, or alkynyl substituted with one or two or 50 three substituents independently selected from the group consisting of cycloalkyl, aryl, heteroaryl, and heterocyclyl;

R^{30} and R^{31} are independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, 55 cycloalkyl, alkyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl,

heterocyclyl, $-\text{NH}_2$, $-\text{NH}(\text{alkyl})$, and $-\text{N}(\text{alkyl})_2$,
- $(\text{CH}_2)\text{alkenyl}$ substituted with one substituent selected
from the group consisting of cycloalkyl, aryl, heteroaryl,
60 heterocyclyl, $-\text{NH}_2$, $-\text{NH}(\text{alkyl})$, and $-\text{N}(\text{alkyl})_2$, or
- $(\text{CH}_2)\text{alkynyl}$ substituted with one substituent selected
from the group consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, $-\text{NH}_2$, $-\text{NH}(\text{alkyl})$, and $-\text{N}(\text{alkyl})_2$;
 R^{32} is $-\text{R}^{26}$, $-\text{C}(\text{O})\text{OR}^{26}$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{C}(\text{O})\text{NHR}^{27}$, or
65 $-\text{C}(\text{O})\text{NR}^{27}\text{R}^{28}$; and
 X^1 is hydrogen or fluoride.

3. The compound of claim 2 having formula (I) or
formula (II), or a pharmaceutically acceptable salt,
prodrug, or salt of a prodrug thereof, in which

R^1 is hydrogen, $-\text{R}^{11}$, $-\text{C}(\text{O})\text{OR}^{11}$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{C}(\text{O})\text{NHR}^{12}$,
5 or $-\text{C}(\text{O})\text{NR}^{12}\text{R}^{13}$;

R^2 is hydrogen or R^{P} , in which R^{P} is a hydroxyl
protecting moiety;

one of R^3 or R^4 is hydrogen and the other is $-\text{OH}$, $-\text{OR}^{\text{P}}$,
or $-\text{OC}(\text{O})\text{R}^{15}$; or

10 R^3 and R^4 together are $=\text{O}$ or $-\text{CH}_2\text{O}-$;

R^5 is hydrogen, $-\text{R}^{19}$, $-\text{C}(\text{O})\text{OR}^{19}$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{C}(\text{O})\text{NHR}^{20}$,
or $-\text{C}(\text{O})\text{NR}^{20}\text{R}^{21}$;

R^6 and R^{10} are independently hydrogen or $-\text{R}^{23}$;

R^7 is $=\text{O}$, $=\text{NOH}$, $=\text{NOR}^{\text{P}}$, or $=\text{NOR}^{24}$;

15 one of R^8 and R^9 is hydrogen, and the other is $-\text{OH}$ or
 $-\text{OR}^{32}$; or

R^8 and R^9 together are $=\text{O}$;

R^{11} , R^{15} , R^{19} , R^{24} , and R^{26} are independently alkyl,
- $(\text{CH}_2)\text{alkenyl}$, $-(\text{CH}_2)\text{alkynyl}$, alkyl substituted with one or

20 two or three substituents independently selected from the
group consisting of cycloalkyl, halo, aryl, heteroaryl, and
heterocyclyl, $-(CH_2)alkenyl$ substituted with one or two or
three substituents independently selected from the group
consisting of cycloalkyl, halo, aryl, heteroaryl, and
25 heterocyclyl, or $-(CH_2)alkynyl$ substituted with one or two
or three substituents independently selected from the group
consisting of cycloalkyl, aryl, heteroaryl, and
heterocyclyl;

R^{12} , R^{13} , R^{20} , R^{21} , R^{27} , and R^{28} are independently alkyl,
30 cycloalkyl, $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, cycloalkyl, aryl,
heteroaryl, heterocyclyl, alkyl substituted with one
substituent selected from the group consisting of
cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$,
and $-NR^{30}R^{31}$, $-(CH_2)alkenyl$ substituted with one substituent
35 selected from the group consisting of cycloalkyl, aryl,
heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, or
 $-(CH_2)alkynyl$ substituted with one substituent selected
from the group consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$;

40 R^{23} is alkyl, alkenyl, alkynyl, aryl, heteroaryl,
heterocyclyl, alkyl substituted with one or two or three
substituents independently selected from the group
consisting of cycloalkyl, halo, aryl, heteroaryl, and
heterocyclyl, alkenyl substituted with one or two or three
45 substituents independently selected from the group
consisting of cycloalkyl, halo, aryl, heteroaryl, and
heterocyclyl, or alkynyl substituted with one or two or
three substituents independently selected from the group
consisting of cycloalkyl, aryl, heteroaryl, and
50 heterocyclyl;

R^{30} and R^{31} are independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, cycloalkyl, alkyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NH(alkyl)$, and $-N(alkyl)_2$, $-(CH_2)alkenyl$ substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NH(alkyl)$, and $-N(alkyl)_2$, or $-(CH_2)alkynyl$ substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NH(alkyl)$, and $-N(alkyl)_2$;
 R^{32} is $-R^{26}$, $-C(O)OR^{26}$, $-C(O)NH_2$, $-C(O)NHR^{27}$, or $-C(O)NR^{27}R^{28}$; and
 X^1 is hydrogen or fluoride.

65

4. The compound of claim 3 having formula (I) or formula (II), or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, in which R^1 is methyl, ethyl, prop-2-ynyl, or prop-2-enyl, each of which is unsubstituted or substituted with one substituent selected from the group consisting of phenyl, quinolinyl, isoquinolinyl, quinazolinyl, and quinoxalinyl in which each substituent is unsubstituted or substituted with one or two substituents independently selected from the group consisting of $-F$, $-Cl$, $-Br$, $-I$ and $-NO_2$; R^2 is hydrogen; R^3 is $-OH$, $((phenyl)carbonyl)oxy$, $((methyl)carbonyl)oxy$, $((trimethylsilyl)oxy)$, or $((triethylsilyl)oxy)$ and R^4 is hydrogen, or R^3 and R^4 together are $=O$ or $-CH_2O-$; R^5 is hydrogen, methyl, ethyl, propyl, prop-2-ynyl, prop-2-enyl, phenylmethyl, 4-methoxyphenylmethyl or 2,4-dimethoxyphenylmethyl; R^6 is hydrogen, methyl, ethyl,

15

ethynyl, or phenyl; R^7 is =O; R^8 is hydrogen and R^9 is -OH, or R^8 and R^9 together are =O; R^{10} is hydrogen, methyl, ethyl, prop-2-ynyl or prop-2-enyl; and X^1 is hydrogen or fluoride.

20

5. The compound of claim 3 having formula (I) or formula (II), or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, in which R^1 is prop-2-ynyl substituted with isoxazolyl, in which the isoxazolyl is substituted with one substituent selected from the group consisting of furyl, imidazolyl, isoquinolinyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, oxazolyl, pyridyl, pyrimidinyl, quinolinyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl, and 1,2,3-triazolyl, in which each substituent is unsubstituted or substituted with one or two substituents independently selected from the group consisting of -F, -Cl, -Br, -I and -NO₂; R^2 is hydrogen; R^3 is -OH, ((phenyl)carbonyl)oxy, ((methyl)carbonyl)oxy, (trimethylsilyl)oxy, or (triethylsilyl)oxy and R^4 is hydrogen, or R^3 and R^4 together are =O or -CH₂O-; R^5 is hydrogen, methyl, ethyl, propyl, prop-2-ynyl, prop-2-enyl, phenylmethyl, 4-methoxyphenylmethyl, or 2,4-dimethoxyphenylmethyl; R^6 is hydrogen, methyl, ethyl, ethenyl, or phenyl; R^7 is =O; R^8 is hydrogen and R^9 is -OH, or R^8 and R^9 together are =O; R^{10} is hydrogen, methyl, ethyl, prop-2-ynyl or prop-2-enyl; and X^1 is hydrogen or fluoride.

20

6. The compound of claim 3 having formula (I) or formula (II), or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, in which R^1 is prop-2-ynyl substituted with thienyl, in which the thienyl is

5 substituted with one substituent selected from the group
consisting of furyl, imidazolyl, isoquinolinyl,
isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, oxazolyl,
pyridyl, pyrimidinyl, quinolinyl, tetrazolyl,
1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl,
10 and 1,2,3-triazolyl, in which each substituent is
unsubstituted or substituted with one or two substituents
independently selected from the group consisting of -F, -Cl,
-Br, -I and -NO₂; R² is hydrogen; R³ is -OH,
(phenyl)carbonyloxy, ((methyl)carbonyloxy,
15 (trimethylsilyl)oxy, or (triethylsilyl)oxy and R⁴ is
hydrogen, or R³ and R⁴ together are =O or -CH₂O-; R⁵ is
hydrogen, methyl, ethyl, propyl, prop-2-ynyl, prop-2-enyl,
phenylmethyl, 4-methoxyphenylmethyl, or
2,4-dimethoxyphenylmethyl; R⁶ is hydrogen, methyl, ethyl,
20 ethenyl, or phenyl; R⁷ is =O; R⁸ is hydrogen and R⁹ is -OH,
or R⁸ and R⁹ together are =O; R¹⁰ is hydrogen, methyl, ethyl,
prop-2-ynyl or prop-2-enyl; and X¹ is hydrogen or fluoride.

7. The compound of claim 3 having formula (I) or
formula (II), or a pharmaceutically acceptable salt,
prodrug, or salt of a prodrug thereof, in which R¹ is prop-
2-enyl substituted with isoxazolyl, in which the isoxazolyl
5 is substituted with one substituent selected from the group
consisting of furyl, imidazolyl, isoquinolinyl,
isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, oxazolyl,
pyridyl, pyrimidinyl, quinolinyl, tetrazolyl,
1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl,
10 and 1,2,3-triazolyl, in which each substituent is
unsubstituted or substituted with one or two substituents
independently selected from the group consisting of -F, -Cl,
-Br, -I and -NO₂; R² is hydrogen; R³ is -OH,

((phenyl)carbonyl)oxy, ((methyl)carbonyl)oxy,
15 ((trimethylsilyl)oxy, or (triethylsilyl)oxy and R⁴ is
hydrogen, or R³ and R⁴ together are =O or -CH₂O-; R⁵ is
hydrogen, methyl, ethyl, propyl, prop-2-ynyl, prop-2-enyl,
phenylmethyl, 4-methoxyphenylmethyl, or
2,4-dimethoxyphenylmethyl; R⁶ is hydrogen, methyl, ethyl,
20 ethenyl, or phenyl; R⁷ is =O; R⁸ is hydrogen and R⁹ is -OH,
or R⁸ and R⁹ together are =O; R¹⁰ is hydrogen, methyl, ethyl,
prop-2-ynyl or prop-2-enyl; and X¹ is hydrogen or fluoride.

8. The compound of claim 3 having formula (I) or
formula (II), or a pharmaceutically acceptable salt,
prodrug, or salt of a prodrug thereof, in which R¹ is
prop-2-enyl substituted with thienyl, in which the thienyl
5 is substituted with one substituent selected from the group
consisting of furyl, imidazolyl, isoquinolinyl,
isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, oxazolyl,
pyridyl, pyrimidinyl, quinolinyl, tetrazolyl,
1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl,
10 and 1,2,3-triazolyl, in which each substituent is
unsubstituted or substituted with one or two substituents
independently selected from the group consisting of -F, -Cl,
-Br, -I and -NO₂; R² is hydrogen; R³ is -OH,
((phenyl)carbonyl)oxy, ((methyl)carbonyl)oxy,
15 ((trimethylsilyl)oxy, or (triethylsilyl)oxy and R⁴ is
hydrogen, or R³ and R⁴ together are =O or -CH₂O-; R⁵ is
hydrogen, methyl, ethyl, propyl, prop-2-ynyl, prop-2-enyl,
phenylmethyl, 4-methoxyphenylmethyl, or
2,4-dimethoxyphenylmethyl; R⁶ is hydrogen, methyl, ethyl,
20 ethenyl, or phenyl; R⁷ is =O; R⁸ is hydrogen and R⁹ is -OH,

or R⁸ and R⁹ together are =O; R¹⁰ is hydrogen, methyl, ethyl, prop-2-ynyl or prop-2-enyl; and X¹ is hydrogen or fluoride.

9. The compound of claim 3 having formula (I) or formula (II), or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, in which R¹ is methyl, prop-2-ynyl, 3-(5-pyridin-2-ylthien-2-yl)prop-2-ynyl, 3-(quinolin-3-yl)prop-2-enyl, 3-(3-pyridin-2-ylisoxazol-5-yl)prop-2-ynyl, or 3-(5-pyrimidin-2-ylthien-2-yl)prop-2-ynyl; R² is hydrogen; R³ is -OH, ((phenyl)carbonyl)oxy, ((methyl)carbonyl)oxy, (trimethylsilyl)oxy, or (triethylsilyl)oxy and R⁴ is hydrogen, or R³ and R⁴ together are =O or -CH₂O-; R⁵ is hydrogen, methyl, ethyl, propyl, prop-2-ynyl, prop-2-enyl, phenylmethyl, 4-methoxyphenylmethyl, or 2,4-dimethoxyphenylmethyl; R⁶ is hydrogen, methyl, ethyl, ethenyl, or phenyl; R⁷ is =O; R⁸ is hydrogen and R⁹ is -OH, or R⁸ and R⁹ together are =O; R¹⁰ is hydrogen, methyl, ethyl, prop-2-ynyl or prop-2-enyl; and X¹ is hydrogen or fluoride.

10. The compound of claim 3 having formula (I) or formula (II), or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, in which R¹ is alkyl, -(CH₂)alkynyl, or -(CH₂)alkynyl substituted with thienyl, in which the thienyl is substituted with pyridyl; R² is hydrogen; R³ is ((phenyl)carbonyl)oxy; R⁴ is hydrogen; R⁵ is hydrogen or alkyl; R⁶ is hydrogen; R⁷ is =O; R⁸ and R⁹ together are =O; R¹⁰ is hydrogen; and X¹ is hydrogen.

11. The compound of claim 3 having formula (I) or formula (II), or a pharmaceutically acceptable salt,

prodrug, or salt of a prodrug thereof, in which R¹ is methyl, prop-2-ynyl or prop-2-ynyl substituted with thienyl, in which the thienyl is substituted with pyridyl; R² is hydrogen; R³ is ((phenyl)carbonyl)oxy; R⁴ is hydrogen; R⁵ is hydrogen or methyl; R⁶ is hydrogen; R⁷ is =O; R⁸ and R⁹ together are =O; R¹⁰ is hydrogen; and X¹ is hydrogen.

12. The compound of claim 10 having formula (I) or formula (II), or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, in which R¹ is methyl; R² is hydrogen; R³ is ((phenyl)carbonyl)oxy; R⁴ is hydrogen; R⁵ is hydrogen or methyl; R⁶ is hydrogen; R⁷ is =O; R⁸ and R⁹ together are =O; R¹⁰ is hydrogen; and X¹ is hydrogen.


13. The compound of claim 10 having formula (I) or formula (II), or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, in which R¹ is prop-2-ynyl; R² is hydrogen; R³ is ((phenyl)carbonyl)oxy; R⁴ is hydrogen; R⁵ is hydrogen or methyl; R⁶ is hydrogen; R⁷ is =O; R⁸ and R⁹ together are =O; R¹⁰ is hydrogen; and X¹ is hydrogen.

14. The compound of claim 10 having formula (I) or formula (II), or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, in which R¹ is 3-(5-pyridin-2-ylthien-2-yl)prop-2-ynyl; R² is hydrogen; R³ is ((phenyl)carbonyl)oxy; R⁴ is hydrogen; R⁵ is hydrogen or methyl; R⁶ is hydrogen; R⁷ is =O; R⁸ and R⁹ together are =O; R¹⁰ is hydrogen; and X¹ is hydrogen.

15. A composition for prophylaxis or treatment of bacterial infections in a fish or a mammal comprising a therapeutically effective amount of a compound of claim 1 and an excipient.


16. Use of a compound of claim 1 for preparation of a medicament for prophylaxis or treatment of bacterial infections.

17. A process for making a compound having formula (I)-b



(I)-b,

5 or a compound having formula (II)-f



(II)-f,

or a salt, prodrug, or salt of a prodrug thereof,
in which

10 R^1 is hydrogen, $-R^{11}$, $-C(O)OR^{11}$, $-C(O)NH_2$,
 $-C(O)NHR^{12}$, $-C(O)NR^{12}R^{13}$, $-CH_2R^{14}$, $-C(O)OCH_2R^{14}$,
 $-C(O)NHCH_2R^{14}$, or $-C(O)N(CH_2R^{14})_2$;

R^5 is hydrogen, $-R^{19}$, $-C(O)OR^{19}$, $-C(O)NH_2$, $-C(O)NHR^{20}$,
15 $-C(O)NR^{20}R^{21}$, $-CH_2R^{22}$, $-C(O)OCH_2R^{22}$, $-C(O)NHCH_2R^{22}$,
or $-OC(O)N(CH_2R^{22})_2$;

R^6 and R^{10} are independently hydrogen or $-R^{23}$;

R^{11} and R^{19} are independently alkyl, $-(CH_2)alkenyl$,
20 $-(CH_2)alkynyl$, alkyl substituted with one, two,
or three substituents independently selected from
the group consisting of cycloalkyl, halo, aryl,
heteroaryl, and heterocyclyl, $-(CH_2)alkenyl$
substituted with one or two or three substituents
independently selected from the group consisting
of cycloalkyl, halo, aryl, heteroaryl, and
25 heterocyclyl, or $-(CH_2)alkynyl$ substituted with
one or two or three substituents independently
selected from the group consisting of cycloalkyl,
aryl, heteroaryl, and heterocyclyl;

R^{12} , R^{13} , R^{20} , and R^{21} are independently alkyl,
30 cycloalkyl, $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, aryl,
heteroaryl, heterocyclyl, alkyl substituted with
one substituent selected from the group
consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$,
35 $-(CH_2)alkenyl$ substituted with one substituent
selected from the group consisting of cycloalkyl,
aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and
 $-NR^{30}R^{31}$, or $-(CH_2)alkynyl$ substituted with one
substituent selected from the group consisting of
40 cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$,
 $-NHR^{30}$, and $-NR^{30}R^{31}$; or

R^{12} and R^{13} together, or R^{20} and R^{21} together are

independently C₃-C₆-alkylene, C₅-C₆-alkylene
interrupted with one moiety selected from the
group consisting of -O-, -NH-, -N(alkyl)-, -S-,
-S(O)-, and -SO₂-, C₃-C₆-alkylene substituted with
one substituent selected from the group
consisting of -OH, -O(alkyl), =O, -NH₂, -NHR³⁰,
and -NR³⁰R³¹, or C₅-C₆-alkylene interrupted with
one moiety selected from the group consisting of
-O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and
substituted with one substituent selected from
the group consisting of -OH, -O(alkyl), =O, -NH₂,
-NHR³⁰, and -NR³⁰R³¹;

R¹⁴ and R²² are independently alkyl interrupted with
one or two or three moieties independently
selected from the group consisting of -O-, -NH-,
-N(alkyl)-, -S-, -S(O)-, and -SO₂- or alkyl
interrupted with one or two or three moieties
independently selected from the group consisting
of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-
and substituted with one or two or three
substituents independently selected from the
group consisting of cycloalkyl, halo, aryl,
heteroaryl, heterocyclyl, -OH, =O, -O(alkyl),
-NH₂, -NHR³⁰, and -NR³⁰R³¹;
R²³ is alkyl, alkenyl, alkynyl, aryl, heteroaryl,
heterocyclyl, alkyl substituted with one, two, or
three substituents independently selected from
the group consisting of cycloalkyl, halo, aryl,
heteroaryl, and heterocyclyl, alkenyl substituted
with one or two or three substituents
independently selected from the group consisting

of cycloalkyl, halo, aryl, heteroaryl, and
75 heterocyclyl, alkynyl substituted with one, two,
or three substituents independently selected from
the group consisting of cycloalkyl, aryl,
heteroaryl, and heterocyclyl, alkyl interrupted
with one or two or three moieties independently
80 selected from the group consisting of -O-, -NH-,
-N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkyl
interrupted with one or two or three moieties
independently selected from the group consisting
of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-
85 and substituted with one or two or three
substituents independently selected from the
group consisting of cycloalkyl, halo, aryl,
heteroaryl, heterocyclyl, -OH, =O, -O(alkyl),
-NH₂, -NHR³⁰, and -NR³⁰R³¹, alkenyl interrupted
90 with one or two moieties independently selected
from the group consisting of -O-, -NH-,
-N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkenyl
interrupted with one or two moieties
independently selected from the group consisting
95 of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-
and substituted with one or two or three
substituents independently selected from the
group consisting of cycloalkyl, halo, aryl,
heteroaryl, heterocyclyl, -OH, =O, -O(alkyl),
100 -NH₂, -NHR³⁰, and -NR³⁰R³¹, alkynyl interrupted
with one or two moieties independently selected
from the group consisting of -O-, -NH-,
-N(alkyl)-, -S-, -S(O)-, and -SO₂-, or alkynyl
interrupted with one or two moieties
105 independently selected from the group consisting

of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-
and substituted with one or two or three
substituents independently selected from the
group consisting of cycloalkyl, halo, aryl,
heteroaryl, heterocyclyl, -OH, =O, -O(alkyl),
-NH₂, -NHR³⁰, and -NR³⁰R³¹; and

R³⁰ and R³¹ are independently alkyl, cycloalkyl, aryl,
heteroaryl, heterocyclyl, -(CH₂)alkenyl,
-(CH₂)alkynyl, cycloalkyl, alkyl substituted with
one substituent selected from the group
consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂,
-(CH₂)alkenyl substituted with one substituent
selected from the group consisting of cycloalkyl,
aryl, heteroaryl, heterocyclyl, -NH₂, -NH(alkyl),
and -N(alkyl)₂, or -(CH₂)alkynyl substituted with
one substituent selected from the group
consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂;


or

R³⁰ and R³¹ together are C₃-C₆-alkylene, C₅-C₆-alkylene
interrupted with one moiety selected from the
group consisting of -O-, -NH-, -N(alkyl)-, -S-,
-S(O)-, and -SO₂-, C₃-C₆-alkylene substituted with
one substituent selected from the group
consisting of -OH, -O(alkyl), =O, -NH₂,
-NH(alkyl), and -N(alkyl)₂, or C₅-C₆-alkylene
interrupted with one moiety selected from the
group consisting of -O-, -NH-, -N(alkyl)-, -S-,
-S(O)-, and -SO₂- and substituted with one
substituent selected from the group consisting of

-OH, -O(alkyl), =O, -NH₂, -NH(alkyl), and
-N(alkyl)₂,


the process comprising the steps of:

140 (a) reacting a compound having formula (X)



(X),

or a compound having formula (IX)




145

(IX),


in which R^P is a hydroxyl protecting moiety and R^{P1} is trimethylsilyl or triethylsilyl, a compound having formula (X²CHR¹⁰CO)₂O, in which X² is -Cl or -Br,

150 and a second base, with or without 4-(N,N-dimethylamino)pyridine, to provide a compound having formula (XI)



(XI),


155 or a compound having formula (XIII)



(XIII),


respectively;

(b) reacting the product of step (a) and a compound
 160 having formula R^5NH_2 to provide a compound having formula
 (XII)



(XII),

or a compound having formula (XIV)




165

(XIV),


respectively;

(c) reacting the product of step (b), a compound having formula R^6CHO , and a first acid, between about 75°C and about 120°C, to provide a compound having formula (I)-a



(I)-a,

or a compound having formula (XV)




175

(XV),

respectively;

(d) reacting the compound having formula (XV) and a fluoride-donating agent then reacting the product obtained therefrom and an oxidant, with or without a second base, to provide a compound having formula (II)-c

180




(II)-c;

and

(e)-(1) reacting the compound having formula (I)-a
185 and a deprotecting agent, or

(e)-(2) reacting the compound having formula (II)-c
and a deprotecting agent.

18. A process for making a compound having formula (II)-g



(II)-g,

5 or a salt, prodrug, or salt of a prodrug thereof, in which
 R^1 is hydrogen, $-R^{11}$, $-C(O)OR^{11}$, $-C(O)NH_2$, $-C(O)NHR^{12}$,
 $-C(O)NR^{12}R^{13}$, $-CH_2R^{14}$, $-C(O)OCH_2R^{14}$, $-C(O)NHCH_2R^{14}$,
or $-C(O)N(CH_2R^{14})_2$;

10 R^5 is hydrogen, $-R^{19}$, $-C(O)OR^{19}$, $-C(O)NH_2$, $-C(O)NHR^{20}$,
 $-C(O)NR^{20}R^{21}$, $-CH_2R^{22}$, $-C(O)OCH_2R^{22}$, $-C(O)NHCH_2R^{22}$,
or $-OC(O)N(CH_2R^{22})_2$;

R^6 and R^{10} are independently hydrogen or $-R^{23}$;

15 R^{11} and R^{19} are independently alkyl, $-(CH_2)alkenyl$,
 $-(CH_2)alkynyl$, alkyl substituted with one, two,
or three substituents independently selected from
the group consisting of cycloalkyl, halo, aryl,
heteroaryl, and heterocyclyl, $-(CH_2)alkenyl$
substituted with one or two or three substituents
independently selected from the group consisting
20 of cycloalkyl, halo, aryl, heteroaryl, and
heterocyclyl, or $-(CH_2)alkynyl$ substituted with
one or two or three substituents independently
selected from the group consisting of cycloalkyl,
aryl, heteroaryl, and heterocyclyl;

25 R^{12} , R^{13} , R^{20} , and R^{21} are independently alkyl,
cycloalkyl, $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, aryl,

heteroaryl, heterocyclyl, alkyl substituted with
one substituent selected from the group
consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH_2 , -NHR^{30} , and $\text{-NR}^{30}\text{R}^{31}$,
 $\text{-(CH}_2\text{)alkenyl}$ substituted with one substituent
selected from the group consisting of cycloalkyl,
aryl, heteroaryl, heterocyclyl, -NH_2 , -NHR^{30} , and
 $\text{-NR}^{30}\text{R}^{31}$, or $\text{-(CH}_2\text{)alkynyl}$ substituted with one
substituent selected from the group consisting of
cycloalkyl, aryl, heteroaryl, heterocyclyl, -NH_2 ,
 -NHR^{30} , and $\text{-NR}^{30}\text{R}^{31}$; or

R^{12} and R^{13} together, or R^{20} and R^{21} together are

$\text{C}_3\text{-C}_6\text{-alkylene}$, $\text{C}_5\text{-C}_6\text{-alkylene}$ interrupted with one
moiety selected from the group consisting of -O- ,
 -NH- , -N(alkyl)- , -S- , -S(O)- , and $\text{-SO}_2\text{-}$,

$\text{C}_3\text{-C}_6\text{-alkylene}$ substituted with one substituent
selected from the group consisting of -OH ,
 -O(alkyl) , =O , -NH_2 , -NHR^{30} , and $\text{-NR}^{30}\text{R}^{31}$, or

$\text{C}_5\text{-C}_6\text{-alkylene}$ interrupted with one moiety
selected from the group consisting of -O- , -NH- ,
 -N(alkyl)- , -S- , -S(O)- , and $\text{-SO}_2\text{-}$ and substituted
with one substituent selected from the group
consisting of -OH , -O(alkyl) , =O , -NH_2 , -NHR^{30} ,
and $\text{-NR}^{30}\text{R}^{31}$;

R^{14} and R^{22} are independently alkyl interrupted with
one or two or three moieties independently
selected from the group consisting of -O- , -NH- ,
 -N(alkyl)- , -S- , -S(O)- , and $\text{-SO}_2\text{-}$ or alkyl
interrupted with one or two or three moieties
independently selected from the group consisting

of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-
and substituted with one or two or three
substituents independently selected from the
group consisting of cycloalkyl, halo, aryl,
heteroaryl, heterocyclyl, -OH, =O, -O(alkyl),
-NH₂, -NHR³⁰, and -NR³⁰R³¹;


R²³ is alkyl, alkenyl, alkynyl, aryl, heteroaryl,
heterocyclyl, alkyl substituted with one, two, or
three substituents independently selected from
the group consisting of cycloalkyl, halo, aryl,
heteroaryl, and heterocyclyl, alkenyl substituted
with one or two or three substituents
independently selected from the group consisting
of cycloalkyl, halo, aryl, heteroaryl, and
heterocyclyl, alkynyl substituted with one, two,
or three substituents independently selected from
the group consisting of cycloalkyl, aryl,
heteroaryl, and heterocyclyl, alkyl interrupted
with one or two or three moieties independently
selected from the group consisting of -O-, -NH-,
-N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkyl
interrupted with one or two or three moieties
independently selected from the group consisting
of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-
and substituted with one or two or three
substituents independently selected from the
group consisting of cycloalkyl, halo, aryl,
heteroaryl, heterocyclyl, -OH, =O, -O(alkyl),
-NH₂, -NHR³⁰, and -NR³⁰R³¹, alkenyl interrupted
with one or two moieties independently selected
from the group consisting of -O-, -NH-,
-N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkenyl

interrupted with one or two moieties
90 independently selected from the group consisting
of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-
and substituted with one or two or three
substituents independently selected from the
group consisting of cycloalkyl, halo, aryl,
95 heteroaryl, heterocyclyl, -OH, =O, -O(alkyl),
-NH₂, -NHR³⁰, and -NR³⁰R³¹, alkynyl interrupted
with one or two moieties independently selected
from the group consisting of -O-, -NH-,
-N(alkyl)-, -S-, -S(O)-, and -SO₂-, or alkynyl
100 interrupted with one or two moieties
independently selected from the group consisting
of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-
and substituted with one or two or three
substituents independently selected from the
105 group consisting of cycloalkyl, halo, aryl,
heteroaryl, heterocyclyl, -OH, =O, -O(alkyl),
-NH₂, -NHR³⁰, and -NR³⁰R³¹; and
R³⁰ and R³¹ are independently alkyl, cycloalkyl, aryl,
heteroaryl, heterocyclyl, -(CH₂)alkenyl,
110 -(CH₂)alkynyl, cycloalkyl, alkyl substituted with
one substituent selected from the group
consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂,
-(CH₂)alkenyl substituted with one substituent
115 selected from the group consisting of cycloalkyl,
aryl, heteroaryl, heterocyclyl, -NH₂, -NH(alkyl),
and -N(alkyl)₂, or -(CH₂)alkynyl substituted with
one substituent selected from the group
consisting of cycloalkyl, aryl, heteroaryl,

120 heterocyclyl, $-\text{NH}_2$, $-\text{NH}(\text{alkyl})$, and $-\text{N}(\text{alkyl})_2$;
 or
 R^{30} and R^{31} together are C_3 - C_6 -alkylene, C_5 - C_6 -alkylene
 interrupted with one moiety selected from the
 group consisting of $-\text{O}-$, $-\text{NH}-$, $-\text{N}(\text{alkyl})-$, $-\text{S}-$,
 125 $-\text{S}(\text{O})-$, and $-\text{SO}_2-$, C_3 - C_6 -alkylene substituted with
 one substituent selected from the group
 consisting of $-\text{OH}$, $-\text{O}(\text{alkyl})$, $=\text{O}$, $-\text{NH}_2$,
 $-\text{NH}(\text{alkyl})$, and $-\text{N}(\text{alkyl})_2$, or C_5 - C_6 -alkylene
 interrupted with one moiety selected from the
 group consisting of $-\text{O}-$, $-\text{NH}-$, $-\text{N}(\text{alkyl})-$, $-\text{S}-$,
 130 $-\text{S}(\text{O})-$, and $-\text{SO}_2-$ and substituted with one
 substituent selected from the group consisting of
 $-\text{OH}$, $-\text{O}(\text{alkyl})$, $=\text{O}$, $-\text{NH}_2$, $-\text{NH}(\text{alkyl})$, and
 $-\text{N}(\text{alkyl})_2$,

135 the process comprising the steps of:

(a) reacting a compound having formula (II)-c



(II)-c,


in which

140 R^{P} is a hydroxyl protecting moiety,
 and a fluorinating agent, with or without a fourth base;
 and

(b) reacting the product of step (a) and a
 deprotecting agent.


145

19. A compound having formula (XI)



(XI),

or a compound having formula (XII),



(XII),

or a salt thereof, in which

R^1 is hydrogen, $-R^{11}$, $-C(O)OR^{11}$, $-C(O)NH_2$, $-C(O)NHR^{12}$, $-C(O)NR^{12}R^{13}$, $-CH_2R^{14}$, $-C(O)OCH_2R^{14}$, $-C(O)NHCH_2R^{14}$, or $-C(O)N(CH_2R^{14})_2$;

R^5 is hydrogen, $-R^{19}$, $-C(O)OR^{19}$, $-C(O)NH_2$, $-C(O)NHR^{20}$, $-C(O)NR^{20}R^{21}$, $-CH_2R^{22}$, $-C(O)OCH_2R^{22}$, $-C(O)NHCH_2R^{22}$, or $-OC(O)N(CH_2R^{22})_2$;

R^{10} is hydrogen or $-R^{23}$;

R^{11} and R^{19} are independently alkyl, $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, alkyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, $-(CH_2)alkenyl$ substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and

heterocyclyl, or $-(CH_2)alkynyl$ substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, aryl, heteroaryl, and

25 heterocyclyl;

R^{12} , R^{13} , R^{20} , and R^{21} are independently alkyl, cycloalkyl, $-(CH_2)alkenyl$, $-(CH_2)alkynyl$, aryl, heteroaryl, heterocyclyl, alkyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, $-(CH_2)alkenyl$ substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, or $-(CH_2)alkynyl$ substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$; or

R^{12} and R^{13} together, or R^{20} and R^{21} together are independently C_3-C_6 -alkylene, C_5-C_6 -alkylene interrupted with one moiety selected from the group consisting of $-O-$, $-NH-$, $-N(alkyl)-$, $-S-$, $-S(O)-$, and $-SO_2-$, C_3-C_6 -alkylene substituted with one substituent selected from the group consisting of $-OH$, $-O(alkyl)$, $=O$, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, or C_5-C_6 -alkylene interrupted with one moiety selected from the group consisting of $-O-$, $-NH-$, $-N(alkyl)-$, $-S-$, $-S(O)-$, and $-SO_2-$ and substituted with one substituent selected from the group consisting of $-OH$, $-O(alkyl)$, $=O$, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$;

R^{14} and R^{22} are independently alkyl interrupted with one or two or three moieties independently selected from the group consisting of $-O-$, $-NH-$, $-N(alkyl)-$, $-S-$, $-S(O)-$, and $-SO_2-$ or alkyl interrupted with one or two or three moieties independently selected from the group consisting of $-O-$,


-NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹;

R²³ is alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, alkyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, alkenyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, alkynyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, aryl, heteroaryl, and heterocyclyl, alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹, alkenyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkenyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O,

- 85 -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹, alkynyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, or alkynyl interrupted with one or two moieties independently selected from the group consisting of -O-,
- 90 -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹;
- 95 R³⁰ and R³¹ are independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -(CH₂)alkenyl, -(CH₂)alkynyl, cycloalkyl, alkyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂,
- 100 -(CH₂)alkenyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂, or -(CH₂)alkynyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl,
- 105 heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂; or
- R³⁰ and R³¹ together are C₃-C₆-alkylene, C₅-C₆-alkylene interrupted with one moiety selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, C₃-C₆-alkylene substituted with one substituent selected
- 110 from the group consisting of -OH, -O(alkyl), =O, -NH₂, -NH(alkyl), and -N(alkyl)₂, or C₅-C₆-alkylene interrupted with one moiety selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted


with one substituent selected from the group consisting of
 115 -OH, -O(alkyl), =O, -NH₂, -NH(alkyl), and -N(alkyl)₂;
 R^P is (methyl)carbonyl or (phenyl)carbonyl; and
 X² is chloride or bromide.

20. A compound having formula (XIII)



(XIII),

or a compound having formula (XIV)



(XIV),

or a salt thereof, in which

R¹ is hydrogen, -R¹¹, -C(O)OR¹¹, -C(O)NH₂, -C(O)NHR¹²,
 -C(O)NR¹²R¹³, -CH₂R¹⁴, -C(O)OCH₂R¹⁴, -C(O)NHCH₂R¹⁴, or
 10 -C(O)N(CH₂R¹⁴)₂;

R⁵ is hydrogen, -R¹⁹, -C(O)OR¹⁹, -C(O)NH₂, -C(O)NHR²⁰,
 -C(O)NR²⁰R²¹, -CH₂R²², -C(O)OCH₂R²², -C(O)NHCH₂R²², or
 -OC(O)N(CH₂R²²)₂;

R¹⁰ is hydrogen or -R²³;

15 R¹¹ and R¹⁹ are independently alkyl, -(CH₂)alkenyl,
 -(CH₂)alkynyl, alkyl substituted with one or two or three
 substituents independently selected from the group

consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, $-(CH_2)$ alkenyl substituted with one or two or
20 three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, or $-(CH_2)$ alkynyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, aryl, heteroaryl, and
25 heterocyclyl;

R^{12} , R^{13} , R^{20} , and R^{21} , are independently alkyl, cycloalkyl, $-(CH_2)$ alkenyl, $-(CH_2)$ alkynyl, aryl, heteroaryl, heterocyclyl, alkyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$,
30 $-(CH_2)$ alkenyl substituted with one substituent selected from the group consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, or $-(CH_2)$ alkynyl substituted with one substituent selected from the group
35 consisting of cycloalkyl, aryl, heteroaryl, heterocyclyl, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$; or

R^{12} and R^{13} together, or R^{20} and R^{21} together are independently C_3 - C_6 -alkylene, C_5 - C_6 -alkylene interrupted with one moiety selected from the group consisting of $-O-$,
40 $-NH-$, $-N(alkyl)-$, $-S-$, $-S(O)-$, and $-SO_2-$, C_3 - C_6 -alkylene substituted with one substituent selected from the group consisting of $-OH$, $-O(alkyl)$, $=O$, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$, or C_5 - C_6 -alkylene interrupted with one moiety selected from the group consisting of $-O-$, $-NH-$, $-N(alkyl)-$, $-S-$, $-S(O)-$,
45 and $-SO_2-$ and substituted with one substituent selected from the group consisting of $-OH$, $-O(alkyl)$, $=O$, $-NH_2$, $-NHR^{30}$, and $-NR^{30}R^{31}$;

R¹⁴ and R²² are independently alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- or alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹;

R²³ is alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, alkyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, alkenyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl, alkynyl substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, aryl, heteroaryl, and heterocyclyl, alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkyl interrupted with one or two or three moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one or two or three substituents independently selected from the group consisting of cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹, alkenyl interrupted with one or two moieties independently selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-, alkenyl interrupted with one or two

80 moieties independently selected from the group consisting of
-O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and
substituted with one or two or three substituents
independently selected from the group consisting of
cycloalkyl, halo, aryl, heteroaryl, heterocyclyl, -OH, =O,
85 -O(alkyl), -NH₂, -NHR³⁰, and -NR³⁰R³¹, alkynyl interrupted
with one or two moieties independently selected from the
group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and
-SO₂-, or alkynyl interrupted with one or two moieties
independently selected from the group consisting of -O-,
90 -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted
with one or two or three substituents independently selected
from the group consisting of cycloalkyl, halo, aryl,
heteroaryl, heterocyclyl, -OH, =O, -O(alkyl), -NH₂, -NHR³⁰,
and -NR³⁰R³¹;
95 R³⁰ and R³¹ are independently alkyl, cycloalkyl, aryl,
heteroaryl, heterocyclyl, -(CH₂)alkenyl, -(CH₂)alkynyl,
cycloalkyl, alkyl substituted with one substituent selected
from the group consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂,
100 -(CH₂)alkenyl substituted with one substituent selected
from the group consisting of cycloalkyl, aryl, heteroaryl,
heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂, or
-(CH₂)alkynyl substituted with one substituent selected
from the group consisting of cycloalkyl, aryl, heteroaryl,
105 heterocyclyl, -NH₂, -NH(alkyl), and -N(alkyl)₂; or
R³⁰ and R³¹ together are C₃-C₆-alkylene, C₅-C₆-alkylene
interrupted with one moiety selected from the group
consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂-,
C₃-C₆-alkylene substituted with one substituent selected
110 from the group consisting of -OH, -O(alkyl), =O, -NH₂,

-NH(alkyl), and -N(alkyl)₂, or C₅-C₆-alkylene interrupted with one moiety selected from the group consisting of -O-, -NH-, -N(alkyl)-, -S-, -S(O)-, and -SO₂- and substituted with one substituent selected from the group consisting of
 115 -OH, -O(alkyl), =O, -NH₂, -NH(alkyl), and -N(alkyl)₂;
 R^P is (methyl)carbonyl or (phenyl)carbonyl;
 R^{P1} is trimethylsilyl or triethylsilyl; and
 X² is chloride or bromide.

21. A compound or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, which is

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-12-fluoro-8-methoxy-3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxohexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca
 5 (1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-ethyl-8-methoxy-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxohexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca
 10 (1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-ethyl-12-fluoro-8-methoxy-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxohexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-8-methoxy-3,4a,6,8,10,12,15a-heptamethyl-2,5,13-trioxo-9-
 20 ((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -3-allyl-15-ethyl-8-methoxy-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 13-trioxo-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -15-ethyl-8-methoxy-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 13-trioxo-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -15-ethyl-12-fluoro-8-methoxy-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 11, 13-tetraoxohexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -15-ethyl-12-fluoro-3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 11, 13-tetraoxo-8-(prop-2-ynyloxy)hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -3-allyl-15-ethyl-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 11, 13-tetraoxo-8-(prop-2-ynyloxy)hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -3-allyl-15-ethyl-12-fluoro-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 11, 13-tetraoxo-8-(prop-2-ynyloxy)hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-12-fluoro-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 11, 13-tetraoxo-8-(prop-2-ynyloxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd) pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 11, 13-tetraoxo-8-(prop-2-ynyloxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd) pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 13-trioxo-8-(prop-2-ynyloxy)-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl) oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd) pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-3-allyl-15-ethyl-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 13-trioxo-8-(prop-2-ynyloxy)-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl) oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd) pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 13-trioxo-8-(prop-2-ynyloxy)-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl) oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd) pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS)-15-ethyl-12-fluoro-3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 11, 13-tetraoxo-8-((3-(5-(pyridin-2-yl) thien-2-yl) prop-2-ynyl) oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca

(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

90 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

95 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-ethyl-12-fluoro-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca

(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

100 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

105 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-12-fluoro-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca

110 (1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-3,4a,6,8,10,12,15a-heptamethyl-2,5,13-trioxo-8-((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy)-9-((3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -3-allyl-15-ethyl-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 13-trioxo-8-((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy)-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -15-ethyl-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 13-trioxo-8-((3-(5-(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy)-9-((3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-11-yl 2, 6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -15-ethyl-3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 11, 13-tetraoxo-8-((3-(5-pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -15-ethyl-12-fluoro-3, 4a, 6, 8, 10, 12, 15a-heptamethyl-2, 5, 11, 13-tetraoxo-8-((3-(5-pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -3-allyl-15-ethyl-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 11, 13-tetraoxo-8-((3-(5-pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy) hexadecahydro-2H-1, 14-dioxo-3-azacyclotetradeca (1, 2, 3-cd)pentalen-9-yl 3, 4, 6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR, 4aS, 6R, 8S, 9R, 10R, 12R, 15R, 15aS, 15bS) -3-allyl-15-ethyl-12-fluoro-4a, 6, 8, 10, 12, 15a-hexamethyl-2, 5, 11, 13-tetraoxo-8-((3-(5-pyrimidin-2-ylthien-2-yl)prop-2-

ynyl) oxy) hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca-
(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -
D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-
155 4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-((3-(5-
pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy) hexadecahydro-2H-
1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-
trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-12-
160 fluoro-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-
((3-(5-pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy)
hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca
(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -
D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-
165 3,4a,6,8,10,12,15a-heptamethyl-2,5,13-trioxo-8-((3-(5-
pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy)-9-((3,4,6-
trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)
hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca
170 (1,2,3-cd)pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-
 α -L-ribo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-
ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,13-trioxo-8-((3-(5-
pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy)-9-((3,4,6-
175 trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)
hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca
(1,2,3-cd)pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-
 α -L-ribo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-
180 4a,6,8,10,12,15a-hexamethyl-2,5,13-trioxo-8-((3-(5-
pyrimidin-2-ylthien-2-yl)prop-2-ynyl)oxy)-9-((3,4,6-
trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)

hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca
(1,2,3-cd)pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-
185 α -L-ribo-hexopyranoside;
(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-
3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-((3-(3-
pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)hexadecahydro-2H-
1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-
190 trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;
(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-12-
fluoro-3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-
((3-(3-pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)
hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca
195 (1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -
D-xylo-hexopyranoside;
(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-
ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-((3-
(3-pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)hexadecahydro-
200 2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl
3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;
(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-
ethyl-12-fluoro-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-
tetraoxo-8-((3-(3-pyridin-2-ylisoxazol-5-yl)prop-2-
205 ynyl)oxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca-
(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -
D-xylo-hexopyranoside;
(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-
4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-((3-(3-
210 pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)hexadecahydro-2H-
1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-
trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;
(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-12-
fluoro-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-

- 215 ((3-(3-pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)
 hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca
 (1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -
 D-xylo-hexopyranoside;
 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-
 220 3,4a,6,8,10,12,15a-heptamethyl-2,5,13-trioxo-8-((3-(3-
 pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)-9-((3,4,6-
 trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)
 hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)-
 pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-
 225 hexopyranoside;
 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-
 ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,13-trioxo-8-((3-(3-
 pyridin-2-ylisoxazol-5-yl)prop-2-ynyl)oxy)-9-((3,4,6-
 trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)
 230 hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)-
 pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-
 hexopyranoside;
 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-
 4a,6,8,10,12,15a-hexamethyl-2,5,13-trioxo-8-((3-(3-pyridin-
 235 2-ylisoxazol-5-yl)prop-2-ynyl)oxy)-9-((3,4,6-trideoxy-3-
 (dimethylamino)- β -D-xylo-hexopyranosyl)oxy)hexadecahydro-2H-
 1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-11-yl 2,6-
 dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;
 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-
 240 3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-(((2E)-
 3-quinolin-3-ylprop-2-enyl)oxy)hexadecahydro-2H-1,14-dioxo-
 3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-
 (dimethylamino)- β -D-xylo-hexopyranoside;
 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-12-
 245 fluoro-3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-
 (((2E)-3-quinolin-3-ylprop-2-enyl)oxy)hexadecahydro-2H-1,14-

dioxa-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-(((2E)-3-quinolin-3-ylprop-2-enyl)oxy)hexadecahydro-2H-1,14-dioxa-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-ethyl-12-fluoro-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-(((2E)-3-quinolin-3-ylprop-2-enyl)oxy)hexadecahydro-2H-1,14-dioxa-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-(((2E)-3-quinolin-3-ylprop-2-enyl)oxy)hexadecahydro-2H-1,14-dioxa-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-12-fluoro-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-8-(((2E)-3-quinolin-3-ylprop-2-enyl)oxy)hexadecahydro-2H-1,14-dioxa-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-3,4a,6,8,10,12,15a-heptamethyl-2,5,13-trioxo-8-(((2E)-3-quinolin-3-ylprop-2-enyl)oxy)-9-((3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)hexadecahydro-2H-1,14-dioxa-3-azacyclotetradeca(1,2,3-cd)pentalen-11-yl 2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-3-allyl-15-ethyl-4a,6,8,10,12,15a-hexamethyl-2,5,13-trioxo-8-(((2E)-3-quinolin-3-ylprop-2-enyl)oxy)-9-((3,4,6-trideoxy-3-

(dimethylamino)- β -D-xylo-hexopyranosyl oxy) hexadecahydro-2H-
280 1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-11-yl 2,6-
dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;
(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-
4a,6,8,10,12,15a-hexamethyl-2,5,13-trioxo-8-((2E)-3-
quinolin-3-ylprop-2-enyl)oxy)-9-((3,4,6-trideoxy-3-
285 (dimethylamino)- β -D-xylo-hexopyranosyl oxy) hexadecahydro-2H-
1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-11-yl 2,6-
dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;
(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-
3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-((3-(5-
290 (pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy) hexadecahydro-2H-
1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-
trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;
(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-8-
methoxy-3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-
295 tetraoxohexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca-
(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -
D-xylo-hexopyranoside;
(2aS,4aR,6R,8S,9R,10R,12R,15R,15aS,15bR)-15-ethyl-8-
methoxy-3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-
300 tetraoxohexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca-
(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -
D-xylo-hexopyranoside;
(2aR,4aS,6R,8S,9R,10S,11S,12R,15R,15aS,15bS)-15-ethyl-
3,4a,6,8,10,12,15a-heptamethyl-2,5,13-trioxo-8-(prop-2-
305 ynyloxy)-9-((3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl oxy) hexadecahydro-2H-1,14-dioxo-3-
azacyclotetradeca(1,2,3-cd)pentalen-11-yl 4-O-benzoyl-2,6-
dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;
(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-
310 3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-(prop-2-

ynyloxy)hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca-
(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -
D-xylo-hexopyranoside; or

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-8-
315 methoxy-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxohexa-
decahydro-2H-1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)-
pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranoside.

22. The compound of claim 21, or a pharmaceutically
acceptable salt, prodrug, or salt of a prodrug thereof,
which is

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-
5 3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-((3-(5-
(pyridin-2-yl)thien-2-yl)prop-2-ynyl)oxy)hexadecahydro-2H-
1,14-dioxo-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl 3,4,6-
trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-8-
10 methoxy-3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-
tetraoxohexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca-
(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -
D-xylo-hexopyranoside;

(2aS,4aR,6R,8S,9R,10R,12R,15R,15aS,15bR)-15-ethyl-8-
15 methoxy-3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-
tetraoxohexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca-
(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -
D-xylo-hexopyranoside;

(2aR,4aS,6R,8S,9R,10S,11S,12R,15R,15aS,15bS)-15-ethyl-
20 3,4a,6,8,10,12,15a-heptamethyl-2,5,13-trioxo-8-(prop-2-
ynyloxy)-9-((3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl)oxy)hexadecahydro-2H-1,14-dioxo-3-

azacyclotetradeca(1,2,3-cd)pentalen-11-yl 4-O-benzoyl-2,6-
dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranoside;
25 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-
3,4a,6,8,10,12,15a-heptamethyl-2,5,11,13-tetraoxo-8-(prop-2-
ynyloxy)-hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca-
(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -
D-xylo-hexopyranoside; or
30 (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-8-
methoxy-4a,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo
hexadecahydro-2H-1,14-dioxo-3-azacyclotetradeca
(1,2,3-cd)pentalen-9-yl 3,4,6-trideoxy-3-(dimethylamino)- β -
D-xylo-hexopyranoside.

35

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/12971

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07H17/08 A61K31/7048 A61P31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07H A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 866 549 A (CHU DANIEL T ET AL) 2 February 1999 (1999-02-02) the whole document -----	1, 15

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 September 2003

Date of mailing of the international search report

07/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

de Nooy, A

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/12971

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5866549	A	02-02-1999	
		AU 729348 B2	01-02-2001
		AU 4178097 A	26-03-1998
		BG 63547 B1	30-04-2002
		BG 103292 A	30-12-1999
		BR 9711661 A	24-08-1999
		CN 1237183 A	01-12-1999
		CZ 9900685 A3	11-08-1999
		EP 1291350 A1	12-03-2003
		EP 1291351 A1	12-03-2003
		EP 1291352 A1	12-03-2003
		EP 1291353 A1	12-03-2003
		EP 0929563 A1	21-07-1999
		HR 970473 A1	31-08-1998
		JP 2001500855 T	23-01-2001
		NO 991022 A	03-05-1999
		NZ 334274 A	23-02-2001
		PL 332009 A1	16-08-1999
		RU 2192427 C2	10-11-2002
		SI 20023 A ,B	29-02-2000
		SK 28699 A3	13-03-2000
		TR 9901127 T2	21-07-1999
		WO 9809978 A1	12-03-1998
		US 6075133 A	13-06-2000
		US 6147197 A	14-11-2000
		US 6028181 A	22-02-2000
		TW 458980 B	11-10-2001
		ZA 9707474 A	23-03-1998